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Abstract 
With  increasing  life  expectancy,  the  rising  incidence  for  osteoporosis-­‐‑induced  fragility  
fractures   such   as   vertebral   compression   fractures   has   become   a   major   public   health  
problem.   Prophylactic   local   treatment   has   emerged   as   a   new   treatment   strategy  
involving  percutaneous  injections  of  biodegradable  and  osteoconductive  augmentation  
materials  into  bones  at  risk  for  osteoporotic  fractures.    
The  work  herein  details   the   successful  development  of   two   in   vivo  animal  models  
for   augmentation   of   cancellous   bone   in   sheep   to   evaluate   the   biocompatibility,  
osteoconductivity  and  degradation  properties  of  new  injectable  composites.    
Using   fluoroscopy   and   a   customized   aiming   device   for   each   animal   model,   the  
biomaterials  were  successfully  injected  with  high  accuracy  and  repeatability  within  the  
inter-­‐‑trabecular  space  of  the  intact  femoral  condyle  and  proximal  tibia  metaphysis  (first  
animal  model)  or   the  cervical  vertebral  bodies   (second  animal  model).  The  suitability  
of   various   biomaterial   formulations   was   investigated   using   specialized   evaluation  
procedures.   In   vivo   florescent   staining   at   6   and   12   weeks   as   well   as   16   weeks   post  
surgery  for  the  cervical  augmentation  model  was  performed  to  detect  enhanced  bone  
activity   in  the  region  of   interest  at  each  time  point.  After  a  12-­‐‑week  follow  up  for  the  
tibia  and  femur  augmentation  and  a  16-­‐‑week  follow  up  for  the  cervical  augmentation,  
the  sheep  were  sacrificed  and  the  injected  bones  harvested  and  evaluated.  For  evidence  
of  new  bone  formation,  radiographs  were  taken  after  sacrifice  using  a  Faxitron.  Micro-­‐‑
Computed   Tomography   measurements   of   the   regions   of   interest   were   taken   to  
qualitatively   assess   bone   volume   density   and   trabecular   thickness.   Qualitative   and  
quantitative   histological   evaluations   were   performed   to   assess   bone   structure,   bone  
remodeling,   percentage   of   new   bone   formation   and   remaining   material   as   well   as  
cellular  reactions  to  the  material.  
Both  animal  models   revealed   to  be  suitable   for   the  evaluation  of  new  biomaterials  
for  prophylactic  augmentation  of  cancellous  bone  in  sheep.  While  the  tibia  and  femur  
augmentation   model   showed   to   be   particularly   suitable   for   screening   studies   to  
evaluate  new  biomaterial  formulations,  the  cervical  augmentation  model  revealed  to  be  
more   challenging   due   to   a   high   rate   of   clinical   relevant   pulmonary   emboli   with  
subsequent  cardiovascular  alterations.    
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Therefore,  this  animal  model  could  be  chosen  to  particularly  study  the  development  
of  a  pulmonary  embolism  and  its  consequences  following  augmentation  of  cancellous  
bone,  as  these  complications  also  occur  in  humans.    
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1 Introduction  
1.1 Overview of osteoporosis and bone augmentation 
Bone  augmentation  of  cancellous  bone  is  a  developing  field  in  orthopedic  surgery  and  
represents  a  treatment  option  for  various  disease  states  in  conjunction  with  loss  of  bone  
mass  and  stability.  
Such  loss  of  bone  integrity  may  be  observed  in  a  range  of  clinical  diseases  caused  by  
osteolytic   tumors,   osteoporosis   and   bone   deformities.   The   affected   patients   can   be  
grouped  by  etiology  into:  the  high-­‐‑energy  trauma  patient,  the  patients  with  tumors,  the  
elderly,  and  the  patients  with  osteoporosis.  Depending  on  the  underlying  disease,  dif-­‐‑
ferent  forms  or  applications  of  bone  augmentation  are  clinically  used.  In  acute  trauma  
patients  with  structural  bone  loss  such  as  the  one  found  in   joint  depression  fractures,  
bone  augmentation  is  commonly  performed  using  autologous  bone  graft.    
Bone  augmentation,  as  applied  to  the  latter  three  patient  groups,  instead  often  uses  
injectable  synthetic  augmentation  materials.    
In  the  elderly  patient,  lack  of  physical  activity  as  well  as  decreased  cellular  regenera-­‐‑
tion  capacity  may  lead  to  a  disturbance  of  the  natural  balance  of  bone  resorption  and  
remodeling.  Hence,   bone  mass   decreases,   stability   is   reduced   and   fracture   healing   is  
delayed.  Tumors  may  be  benign  (hemangioma)  or  include  malignant  lesions  (metastat-­‐‑
ic  cancers,  myeloma).  Loss  of  bone  mass  in  tumor  patients  is  the  primary  factor  leading  
to  instability,  pathological  fractures  as  well  as  bone  cysts.  Finally,  osteoporosis  patients  
represent  the  single  largest  patient  group  undergoing  augmentation  procedures  using  
synthetic  bone  cements.  Osteoporosis  may  be  classified  as  primary  osteoporosis,  affect-­‐‑
ing  juvenile,  postmenopausal  or  senile  patients.  It  may  also  be  classified  as  secondary  
osteoporosis,   being   the   result   of   another   underlying   disease   (e.g.,   congenital,   hy-­‐‑
pogonadal,   endocrine,   inflammatory,   cancer),   various   deficiency   states   (e.g.,   calcium,  
magnesium,   protein,  Vit.D,  malabsorption,   gastrectomy),   drug-­‐‑induced   alterations   in  
bone  metabolism   (e.g.,   antipsychotic,   antiretroviral,   and   anticonvulsant   drugs)   or   an  
altered  metabolism  due  to  alcohol  abuse.  By  far,  the  most  common  form  of  osteoporo-­‐‑
sis  encountered  today  is  primary  osteoporosis  in  postmenopausal  and  senile  patients;  a  
patient   group   frequently   burdened   also   with   other   diseases   and   comorbidities   and  
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therefore   must   be   seen   as   a   high-­‐‑risk   patient   group.   Better   treatment   modalities  
through   bone   augmentation   with   biomimetic   injectable   composites   are   urgently   re-­‐‑
quired  to  enhance  bone  mineral  density  (BMD)  and  prophylactically  stabilize  bones  at  
risk  for  fracture.  
  
1.2 Fragility fractures and fracture fixation failures in osteoporotic bone 
Fragility   fractures   are   a   major   public   health   problem,   particularly   in   the   elderly  
population   due   to   increased   life   expectancy,   affecting   up   to   9   million   people  
worldwide  each  year  [1].  While  in  younger  patients  the  main  fracture  etiology  is  high-­‐‑
energy  trauma  [2],  in  the  geriatric  population  the  largest  proportion  of  fractures  occurs  
after   falls   from   a   standing   or   sitting   position   and/or   other   low-­‐‑energy   trauma.   This  
could   be   attributed   to   the   aging   skeleton   and/or   osteoporosis,   where   compromised  
bone  regeneration  capacity  is  increasing  the  fracture  risk.  [3-­‐‑7].    
Osteoporosis  is  a  systemic  skeletal  disease,  characterized  by  an  overall  loss  of  bone  
density  [8]  and  a  reduction  in  bone  quality  by  microarchitectural  deterioration  such  as  
reduction,  thinning  and  disconnection  of  the  trabeculae  from  each  other  and  from  the  
surrounding   cortical   bone   (Figure   1.1).   These   alterations   increase   bone   fragility   and  
susceptibility   to   fractures.   An   imbalance   of   osteoblast   and   osteoclast   activity   shifts  
bone  remodeling   towards  resorption.  The  metaphyseal   regions  with  high  amounts  of  
cancellous  bone  -­‐‑  especially  the  proximal  femur,  distal  radius,  proximal  humerus  and  
vertebrae  -­‐‑  are  primarily  affected  and  are  particularly  at  risk  for  fractures  [9].    
  
Figure 1.1: Micro-CT images of healthy (left) and osteoporotic (right)  
human trabecular bone. Reduction, thinning and disconnection of  
trabeculae characterize the osteoporotic bone. 
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As  a   consequence  of   the  osteoporotic,  weakened  bone  and   the   compromised  bone  
regeneration   at   the   cellular   and  molecular   level,   also   fracture   fixation   failures   occur  
more  often   in   the   elderly.  Reduced   stability  of   fixation   screws   leads   to   screw  cut-­‐‑out  
and   implant   migration,   especially   in   hip   [5,10],   vertebral   [11-­‐‑13],   and   humerus  
fractures  [14,15].      
Additionally,  comorbidities   in  geriatric  patients  contribute  to  the  cause  of  fracture,  
but  also  provoke  significant  post  interventional  complications  (e.g.  delirium,  infection,  
kidney  failure)  and  high  mortality  rates  [16-­‐‑18].  For  example,  hip  fractures,  being  one  
of  the  most  common  osteoporotic  fractures,  are  caused  by  low-­‐‑energy  trauma  in  90%  of  
the  cases  and  are  associated  with  a  first  year  mortality  up  to  30%,  as  well  as  very  high  
disability  and  poor  functional  outcome  [17,19,20].  
Therefore,   the   surgical   and   overall  management   of  multimorbid   geriatric   patients  
suffering   from   fragility   fractures   is   highly   demanding.   Co-­‐‑management   by  
geriatricians   and   orthopedic   surgeons,   combined   with   standardized   care,   reduced  
waiting  time  for  surgery,  reduced  surgery  time  and  technical   innovations  will   lead  to  
improved   overall   outcomes.   New   implants   featuring   conduits   to   add   cement   for  
supplemental   fixation   for   standardized   cement   augmentation   [16,17]   represent   a   new  
class  of  instruments  used  to  treat  fragility  fractures.  
  
1.3 Indications for augmentation of cancellous bone 
Cancellous   bone   augmentation   is   commonly   used   to   mechanically   enhance   bone  
structure  and/or  implant  fixation  in  weakened  and  osteolytic  bone  with  low  BMD.  It  is  
proven  effective  in  stabilizing  deteriorated  or  fractured  bone  for  filling  bone  voids  and  
enhancing   anchorage   for   implants   at   risk   for   loosening.   Different   augmentation  
techniques   and   materials   (e.g.,   autograft,   allograft,   polymethyl-­‐‑metacrylate   (PMMA)  
bone   cement,   tricalciumphosphate,   hydroxyapatite)   are   used   at   various   anatomical  
locations  for  therapeutic  or  prophylactic  indications,  or  a  combination  of  both.    
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1.3.1 Therapeutic indications for cancellous bone augmentation 
1.3.1.1 Implant augmentation 
Reduced  bone  mass  due  to  osteoporosis  or  cancer  induced  osteolysis  leads  to  implant  
failures,  affecting  mainly  metaphyseal  regions,  the  head-­‐‑neck  fragment  of  the  hip  and  
the  vertebral  bodies.  Changes   in  the  cancellous  bone  due  to  osteoporosis   (see  chapter  
1.2)   lead   to   a   smaller   bone-­‐‑implant   contact   area   and,   subsequently,   to   a   decrease   of  
holding   power   for   implants.   In   order   to   alleviate   these   problems,   implant  
augmentation   with   PMMA   bone   cement   can   be   performed.   This   expands   the   bone-­‐‑
implant   interface   and   provides   enhanced   implant   anchorage   with   higher   stability  
[17,21].  Especially   in  cases  of   revision  surgery  after  previous   implant   failure,   implant  
augmentation  has  shown  good  results  with  enhanced  implant  anchorage  and  reduced  
risk  for  refracture  or  other  complications  [22].  
The   indication   for   implant   augmentation   is   based   on   multiple   relevant   criteria:  
preoperative  radiographic  findings,   the  age  of  the  patient  (e.g.,  guiding  principle  that  
all   hip   fractures   in   patients   older   than   80   years   should   be   augmented)   and  
intraoperative  subjective  assessment  of  bone  softness.  The  ad-­‐‑hoc  intraoperative  use  of  
a   newly   developed   densitometer   (DensiProbe®)   to   measure   the   peak   breakaway  
torque  of  trabecular  bone  may  provide  the  surgeon  with  biomechanical  information  on  
local   bone   strength   [23-­‐‑25].   Despite   supportive   evidence   however,   DensiProbe®   has  
not  achieved  yet  a  clinical  breakthrough.    
Different   ex-­‐‑vivo   studies   have  demonstrated   superior   biomechanics   (higher   failure  
loads,  higher  number  of   load  cycles  to  failure)  following  implant  augmentation  using  
PMMA  cements  for  osteoporotic  regions  at  risk  for  implant  loosening.  In  these  studies,  
in   situ   augmented   cannulated   implants   were   used   for   vertebrae   [26,27],   proximal  
humerus  [28],  and  proximal  femur  [29,30].  
In  a  biomechanical  study  of  Sermon  et  al.  using  human  cadaveric  femoral  heads,  the  
implants  sustained  on  average  51%  more   load  cycles   following  cement  augmentation  
[30].  No  correlation  was  found  between  BMD  and  the  number  of  load  cycles  to  failure  
when   using   augmented   implants.   These   results   support   the   hypothesis   that  
augmentation   reduces   the  adverse   effects  of   low  bone  quality   and  hence   reduces   the  
negative  impact  of  osteoporosis  on  implant  anchorage.  However,  with  increasing  bone  
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quality,   a   reduced   augmentation   effect   was   observed,   suggesting   that   PMMA  
augmentation  is  primarily  useful  in  weakened  osteoporotic  bone.  This  was  illustrated  
by   an   inversely   related   impact   of   cement   augmentation   with   respect   to   the   BMD  
[28,30].  Therefore,  augmentation  with  PMMA-­‐‑cement  should  only  be  performed  after  
thorough  risk-­‐‑benefit-­‐‑analysis  in  weakened  bone  with  low  BMD  values.    
Implant  augmentation  is  categorized  in  standardized  and  non-­‐‑standardized  techniques.  
For   standardized   augmentation,   implants   featuring   conduits   to   add   cement   for  
supplemental   fixation   have   been   specifically   developed.   The   standardization   often  
includes   the   development   of   guiding   instruments   for   reproducible   implantation   and  
subsequent  augmentation.    
Standardized   implants   are   available   for   treatment   of   hip   fractures   [22,29-­‐‑32],  
proximal   humerus   fractures   [33]   and   for   spinal   instrumentations   [13,34-­‐‑36].   Three  
examples  are  listed  here:  
1. Proximal  Femur  Nail  AntirotationTM  Augmentation  (PFNATM  Augmentation,  DePuy	  Synthes	   Companies	   Trama,	   Zuchwil,	   Switzerland):   This   intramedullary   nail   with   a  
helical   blade   (including   augmentation   option)   was   designed   for   better   rotational  
stability  and  resistance  to  cut-­‐‑out  within  the  femoral  head  [37].  The  injected  cement  
surrounding   the   tip   of   the   helical   blade   results   in   a   greater   load-­‐‑bearing   surface  
with  improved  initial  stability  and  the  possibility  of  immediate  full  weight-­‐‑bearing  
[32].   The   improved   anchorage   is   most   effective   in   osteoporotic   bone   and   could  
prevent   further   clinical   interventions   within   the   geriatric   patient   group.   A  
maximum  cement  volume  of  3  mL  should  be  used  for  augmentation.  
  
Figure 1.2: Schematic illustration of an implanted augmented PFNATM. The 
injected cement surrounds the tip of the helical plate in a cloud-like shape.  
(http://www.synthes.com/MediaBin/International%20DATA/036.001.143.pdf) 
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2. Proximal  Humeral   Internal   Locking   System   (PHILOS  AUGMENTATION,  DePuy  
Synthes   Trauma):   It   was   developed   for   internal   fixation   of   proximal   humerus  
fractures  using  locking  screws  with  perforations  at  their  tip  for  screw  augmentation  
in   combination   with   a   locking   compression   plate.   Biomechanical   studies   have  
shown  enhanced  anchorage  in  low-­‐‑density  bone  after  augmentation  of  the  fixation  
screws  placed   in   the  head   [28,38].   Every   screw   is   augmented  with  maximally   0.5  
mL  of  cement  with  a  maximum  of  3  mL  cement  for  all  augmented  screws.  
 
Figure 1.3: Schematic fluoroscopy image of a PHILOS locking plate 
in combination with two augmented perforated locking screws.  
(http://www.synthes.com/sites/intl/IntlContent/Files/016.001.576.pdf) 
  
3. MATRIX   spine   system   (DePuy   Synthes   Spine):	   Posterior	   pedicle	   screw	   and	   hook	  fixation	  system	  for	  precise	  and	  segmental	  stabilization	  of	  the	  spine.	  Perforated	  pedicle	  screws	  for	  augmentation	  feature	  six	  radial	  openings	  for	  360°	  cement	  distribution	  (in	  a	  cloud	  like	  shape)	  applied	  only	  after	  final	  screw	  positioning.	  Each	  screw	  is	  augmented	  approximately	  2-­‐3	  mL	  of	  cement.	  
  
Figure 1.4: Schematic illustration of a bisected vertebra and 
perforated pedicle screw showing the cloud like distribution of the 
bone cement. 
(http://www.synthes.com/MediaBin/International%20DATA/036.001.
197.pdf)  
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If   standardized   implants   and   guiding   instruments   are   not   available   for   a   specific  
anatomical   site   and/or   type  of   fracture,  non   standardized   augmentation   techniques  are  
used.   Especially   for   tumor   surgeries,   involving   osteolytic   bone,   non   standardized  
implant   augmentation   and   void   filling   techniques   are   performed.   Implantation   and  
augmentation   steps  are   then   switched   such   that  after  drilling  and   thread  cutting,   the  
bone   is   first  augmented  and   then  only  conventional  non  canulated/perforated  screws  
are  implanted  in  the  cement  prefilled  site.  Such  procedures  could  also  be  performed  for  
intramedullary  nails  and  other  non-­‐‑standardized  implants.    
1.3.1.2 Void filling 
Currently,  void  filling  is  used  in  spine  and  trauma  surgery.  
In  trauma  surgery,  bone  voids  are  frequently  seen  as  a  result  of  an  acute  metaphyseal  
and   joint  depression  fracture  with  impaction  of  the  underlying  cancellous  bone,  or  as  
the  result  of  an  acute  dislocation  and  depression  of  the  articular  surface  (e.g.,  proximal  
tibia,   distal   femur,   calcaneus).  Whether   acutely   traumatic   or   surgically   created   after  
fracture   reduction   and   fixation,   bone   voids   need   to   be   filled   to   prevent   long-­‐‑term  
complications  such  as  posttraumatic  arthritis,  pain  and  limited  range  of  motion  due  to  
joint   surface   depression   [39].   The   gold   standard   for   this   type   of   fractures   remains  
autologous   bone   graft   (cancellous   or   corticocancellous)   because   of   its   combined  
osteoinductive,   osteoconductive   and   osteogenic   properties   [40].   It   can   be   used   to  
replace   regions   of   bone   loss   caused   by   comminution   or   crushing,   thus   enhancing  
fracture  construct  stability.    
The   iliac   crest   is   the  most   common  donor   site   for   autografts.  However,   in   elderly  
osteoporotic  patients,  the  quantity  and  quality  of  bone  available  from  the  iliac  crest  is  
often   inferior.  This  usually   requires  a   larger  exposure,   leading   to  an   increased  risk  at  
the   donor   site   and   other   morbidities,   such   as   chronic   pain   and   wound   dehiscence  
[41,42].  Allograft  bone  and  synthetic  bone  void  fillers  could  be  used  as  alternative  graft  
materials  for  fracture  void  filling.  Bone  allografts  avoid  donor  site  morbidity,  but  still  
provide   most   of   the   beneficial   properties.   However,   it   can   lead   to   other   serious  
complications,   including   histoincompatibility,   disease   transmission   and   more  
frequently   non-­‐‑unions.   To   avoid   the   above   complications,   synthetic   bone   void   fillers  
Introduction  
8  
(e.g.,   calcium   phosphate   cements)   have   lately   used.   Ideally,   these   synthetic   fillers  
should   contain   bioactive   and   biocompatible   components   and   offer   compressive  
strength   to   achieve   immediate   load   bearing,   thus   decreasing   the   risk   of   secondary  
fracture   dislocation   causing   long-­‐‑term   complications.   Rapidly   degrading   synthetic  
bone  filler  is  likely  to  induce  rapid  new  bone  formation  at  the  resorption  site.    
Calcium   phosphate   based   bone   cements   have   already   been   used   successfully   for  
bone   void   filling   following   tibial   plateau   [43-­‐‑45]   and   calcaneus   [46,47]   fracture  
reduction   and   internal   fixation.   For   both   fracture   types,   bone   void   filling   following  
surgical   reduction  allows  early   load  bearing,  without   radiological   evidence  of   loss  of  
reduction.  
In  spine  surgery,  percutaneous  vertebroplasty  (PVP)  and  balloon  kyphoplasty  (BKP)  
are   both   popular   minimally   invasive   augmentation   procedures   for   the   treatment   of  
painful  vertebral  compression  fractures  caused  by  osteoporosis,  benign  (hemangioma)  
or  malignant   lesions   (metastatic   cancer,  myeloma)   [48-­‐‑55].   These  minimally   invasive  
techniques  can  provide  immediate  pain  relief  and  in  case  of  BKP  also  reduce  kyphotic  
deformity  and  realign  the  spine.  Both  techniques  are  particularly  indicated  in  patients,  
where   internal   fixation   techniques   (like   instrumented   long  posterior  or  posterolateral  
spinal  fusion)  is  contraindicated  due  to  bone  fragility.    
The  PVP  technique  was  introduced  in  1984  by  Galibert  and  Deramond  [56]  and  is  a  
fluoroscopy-­‐‑guided   procedure,   involving   percutaneous   injection   of   PMMA   bone  
cement  into  a  fractured  vertebral  body.  Using  PVP  to  stabilize  the  fracture,  pain  relief  
is   achieved  by   fracture   stabilization   and  decompression   in   80%   -­‐‑   90%  of   the  patients  
[57].  However,  existing  kyphotic  deformity  or  reduced  vertebral  body  height  cannot  be  
restored.  Cement  distribution   from  endplate   to  endplate   is   important   to  achieve  pain  
relief.  An  angulated  unipedicular  approach  is  sufficient  as   long  as   the  cement  crosses  
the  vertebras  midline  [58].  The  unipedicular  approach  leads  to  a  reduced  surgery  time  
and   decreased   risk   for   venous   or   epidural   cement   extravasation   [59].   The   entire  
injection  procedure,  however,  has   to  be  performed  under  high  quality   fluoroscopy  to  
monitor   the   expanding   cement   cloud.   If   extravasation   occurs,   the   injection   has   to   be  
stopped   immediately   and   the   needle   repositioned   to   prevent   pulmonary   cement  
embolism  or  cement  leakage  into  the  spinal  canal.    
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Depending   on   the   clinical   situation   (vertebra   size,   fracture   type,   progression   of  
osteoporosis)   an   average   of   3-­‐‑6   mL   bone   cement   is   commonly   injected   per   lumbar  
vertebra.  For  multiple  level  augmentations  a  maximum  of  25  mL  (less  in  patients  with  
severe  compromised  heart  and  lung  function)  and  six  augmented  vertebrae  per  session  
are   advocated   to   avoid  possible   fat   and   cement   embolism   [60].   Both,   the  use  of  high  
viscosity   cement   and   limiting   the   injected   cement   volume   to   the  minimum   required  
reduce   the   risk   of   cement   extravasation   and   leakage   [61,62].   The  minimum   required  
amount  of  cement  is  somewhat  subjective  and  dependent  on  a  surgeon’s  experience.  
In  1998,  balloon  kyphoplasty  (BKP)  was  introduced,  adding  an  additional  step  prior  
to  cement  injection,  rendering  BKP  a  slightly  more  invasive  procedure  than  PVP.  The  
surgical   procedure   takes   much   longer   and   thus   has   to   be   performed   always   under  
general  anesthesia.  An  inflatable  balloon  tamp  is  placed  in  the  fractured  vertebral  body  
creating  a  cavity  within  the  vertebral  body  [50,63].  Guided  over  bipedicular  cannulas,  
two   ballons   are   inserted   using   fluoroscopy,   then   inflated   to   a   maximum   pressure  
monitored  with  a  digital  manometer.  A  cavity   is   created  and   the   fractured  vertebra’s  
height   is  restored.  Subsequently,   the  balloons  are  deflated  and  removed.  Low  cement  
pressure  is  used  to  fill  the  cavities  [64]  with  2-­‐‑6  mL  of  high  viscosity  cement  per  side.  
Using  bilateral  balloons,  correction  of  a  kyphotic  deformity  (defined  as  a  segmental  
kyphosis   of   >   6°)   is   achieved   with   70%   restoration   of   the   vertebras   original   height  
[18,50,65-­‐‑67].   Treatment   of   acute   vertebral   compression   fractures   with   associated  
kyphotic  deformity  using  BKP  may  relief  pain  in  90%  of  the  patients  [50],  stabilizes  the  
fracture,   restores   vertebral   body   height   and   avoids   pulmonary   and   gastrointestinal  
complications  usually  associated  with  severe  kyphosis.  
1.3.2 Prophylactic indications for cancellous bone augmentation 
Prophylactic  augmentation  is  typically  a  minimally  invasive  mechanical  augmentation  
procedure  to  stabilize  weakened,  osteoporotic  or  osteolytic  bone  at  risk  for  fracture.  If  
possible   the   procedure   is   performed   percutaneously   via   injection   of   an   adequate  
augmentation   material   into   the   intertrabecular   space.   To   date,   prophylactic  
augmentation  is  only  used  in  two  anatomical  locations:  spine  and  hip.    
Introduction  
10  
In  spine  surgery,  prophylactic  percutaneous  vertebroplasty  of  unaffected  vertebral  
bodies   adjacent   to   fractured   and   already   augmented   vertebra   is   thought   to   prevent  
additional  fractures  [68,69]  and  thereby  avoiding  deterioration  of  the  patient’s  quality  
of   life  due   to  chronic  pain   [70]  and  kyphosis  progression.  Prophylactic  augmentation  
may   be   performed   in   combination   with   implant   augmentation   (pedicle   screw  
augmentation),   or   in   combination   with   multi-­‐‑segmental   posterior   spinal  
instrumentation,   this   to  prevent   fractures   at   the  upper  most  vertebra   included   in   the  
construct   and   the   adjacent   un-­‐‑instrumented   vertebra.   Combined   treatment   may  
decrease   the   risk   of   adjacent   segment   disease   next   to   a   rigid   fixation,   especially   in  
patients  that  already  have  an  established  osteoporosis  [71].    
In  some  hospitals,  prophylactic  augmentation  of  the  contralateral  hip  is  performed  
concurrently   with   fixation   of   prosthetic   replacement   of   a   primary   hip   fracture.  
(Personal   communication   with   Prof.  M.   Blauth;   University   hospital   Innsbruck).   This  
prophylactic  procedure  reduces  the  risk  of  a  contralateral  primary  hip  fracture,  which  
otherwise  is  about  10%  in  the  first  five  years  following  the  initial  fracture.  
Currently,   prophylactic   augmentation   is   performed   using   exclusively   non-­‐‑
resorbable  PMMA  bone  cement.    
1.4 Injectable augmentation materials  
An   adequate   injectable   augmentation   material   should   feature   the   following  
properties:  High  radiopacity  for  visibility  during  injection,  low  curing  temperature,  no  
cytotoxicity   and   adequate  mechanical   properties   (tensile   strength,   bending  modulus,  
compressive   strength).   Additionally,   the   cured   material   should   have   microporosity  
(mean   pore   diameter   <10   γm;   to   allow   circulation   of   body   fluid)   as   well   as  
macroporosity   (mean   pore   diameter   >100   γm;   to   provide   a   scaffold   for   blood-­‐‑cell  
colonization).   The   latter   are   mandatory   features   for   sufficient   bone   ingrowth,   for  
osteoinductivity,  osteoconductivity,  and  bioactivity  [72].  
Injectable   bone   cements   used   for   augmentation   are   classified   based   on   their  
chemistry   as   acrylic   bone   cements,   as   ceramic  bone   cements   (calcium  phosphate   and  
calcium  sulfate  based),  and  as  filamentary  composite  materials  [73].    
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To  date,  only  acrylic  bone  cements  and  acrylic  based  composites  offer  the  required  
mechanical   strength   for   high   load-­‐‑bearing   applications   (e.g.,   implant   augmentation,  
anchoring  of   total   joint   replacements).  Calcium  phosphate   and   calcium   sulfate   based  
cements   are   typically  used  as  bone  void   fillers   or   bone  graft   substitutes   in   low   load-­‐‑
bearing   applications.   In   medium   load-­‐‑bearing   applications   (e.g.,   PVP,   BKP)   mainly  
acrylic  cements  are  used,  but  rarely  also  calcium  phosphate  based  bone  cements.  
1.4.1 Acrylic bone cements and their composites 
Currently,   the   most   widely   used   injectable   acrylic   bone   cement   is  
polymethylmethacrylate  (PMMA).   It  has  been  used  in  orthopedics  since  the  1940s  for  
open   joint   replacements   [74].   The   first   commercially   available   PMMA   cement   was  
introduced  in  1966  and  specifically  designed  for  joint  replacements.  Much  later  it  was  
used   as   injectable   material   to   augment   and   stabilize   osteoporotic   bone.   For   decades  
PMMA  was   the   only   available   injectable   polymer   usually   combined  with   a   contrast  
agent   (e.g.,   barium   sulfate,   zirconium   oxide)   to   allow   for   radiographic   cement  
visualization  during  injection.    
PMMA  is  composed  of  a  prepolymerized  powder  and  a  liquid  monomer,  initiating  
an  exothermic  polymerization  reaction  when  combined.  The  curing  process  is  divided  
into   four  phases:  mixing,   adhering,  working,   and  hardening.  Commercially   available  
PMMA   cements   can   be   categorized   as   low   or   high   viscosity   cements   depending   on  
which  phase  predominates  during  the  curing  process.  Low  viscosity  cements  typically  
have  a  longer  sticky  phase  and  a  shorter  working  phase,  high  viscosity  cements  behave  
opposite.   The   mechanical   properties   of   PMMA   are   between   that   of   cancellous   and  
cortical  bone,  having  a  high  compressive  strength   [74],  a  4   -­‐‑  40   times  higher  bending  
(Young’s)  modulus   than   cancellous  bone   [75,76]   and  a   relatively   low   tensile   strength  
[77]  (Table  1.1).  
   PMMA   Cancellous  Bone   Cortical  Bone  
Compressive  strength  (MPa)   85  -­‐‑  110      133  -­‐‑  193  
Bending  (Young’s)  modulus  (GPa)   2  -­‐‑  3   0.05  –  0.8   10  -­‐‑  20  
Tensile  strength  (MPa)   30  -­‐‑  51      51  -­‐‑  133  
Table 1.1: Compressive strength, bending modulus and tensile strength of PMMA, cancellous bone and 
cortical bone. 
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Cured   PMMA   is   bioinert   with   good   long-­‐‑term   biocompatibility   [78].   However,  
PMMA  has   several   disadvantages:   Because   it   is   neither   integrated   nor   remodeled,   it  
stays   in   the   bone   like   a   placeholder.   At   higher   strain   rates   PMMA   cement   becomes  
stiffer,   leading   to   an   increased   risk   of   adjacent   vertebral   fractures   [79,80].   The   high  
polymerization   temperature  may   cause   thermal   damage   and   subsequent   necrosis   to  
surrounding   bone   or   cartilage   tissue   [81,82].   Incomplete   polymerization   may   cause  
monomer  toxicity  [83].    
To   address   the   disadvantages   of   PMMA,   composites   of   acrylic   bone   cements   in  
conjunction   with   ceramics   are   currently   favored   for   PVP,   BKP   and   for   implant  
augmentation.   Cement   composites   containing   PMMA   and   various   ceramic  
components,   e.g.   Traumacem®      (DePuy   Synthes   Companies,   Zuchwil,   Switzerland)  
with  45%  w/v  PMMA  and  55%  w/v  ceramic  components  (40%  zirconium  dioxide,  15%  
hydroxyapatite),   have   shown   in   various   medium   to   high   load   bearing   applications  
improved   handling   and   clinical   outcomes   compared   to   PMMA   alone   [29-­‐‑32].   These  
composites  are  ready  to  use  immediately  after  mixing  and  show  enhanced  viscosity  for  
controlled   injections   with   improved   flow   properties   and   increased   working   time  
(27min   at   room   temperature,   15min   at   body   temperature).   Due   to   a   decrease   of  
polymerization  temperature  (60°C),  no  thermal  damage  to  surrounding  tissue  may  be  
observed.  However,   the  bending  modulus  as  well   as   the  yield   strength  of  Vertecem®  
(DePuy  Synthes  Companies,  Zuchwil,  Switzerland),  used  for  PVP,  is  still  much  higher  
than  that  of  cancellous  bone,  which  could  lead  to  a  load  shift  to  the  adjacent  vertebra  
with  an  increase  of  the  risk  for  fracture.  
In   an   in   vitro   study   of   Boger   et   al.   the   mechanical   properties   of   a   low   modulus  
PMMA  bone   cement  were   investigated   for   augmentation   of   osteoporotic   bone.   They  
produced   porous   PMMA   bone   cements,   thereby  mixing   commercial   PMMA   cement  
(Vertecom®,   DePuy   Synthes)   with   various   volume   fractions   (15-­‐‑50%)   of   an   aqueous  
sodium  hyaluronate   solution.  Mechanical  properties   for   composites  with  35-­‐‑45%  w/v  
sodium   hyaluronate   solution   were   promising.   Bending   modulus   and   yield   strength  
were  similar  to  those  of  cancellous  bone,  the  polymerization  temperature  much  lower  
(<  41°C),  but  injectability,  viscosity  and  monomer  release  were  unaffected  [76].  All  tests  
were  performed  using  only  non  fractured  vertebra,   leading  to  the  conclusion  that   the  
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application  of  porous  PMMA  cement  for  prophylactic  vertebroplasty  may  successfully  
reinforce   non-­‐‑fractured   osteoporotic   bone   without   modifying   the   stress   distribution  
und  physiological  loading  significantly  [84].    
In   studies  of  Hernandez   et   al.   the  main   focus  was   to   improve   the  biocompatibility  
and   osseointegration   of   PMMA   bone   cement   combined  with   a   bioactive   component  
(20%   w/v   strontium-­‐‑hydroxyapatite).   The   newly   developed   cements   demonstrated  
enhanced   handling   properties,   optimum   injectability   and   could   withstand   wear  
conditions  [85].  They  presented  homogenous  radiopacity  and  an  excellent   in  vitro  and  
in   vivo   bioactivity   [86].   Future   studies   are   required   for   preclinical   tests   of   this  
promising   composite   as   alternative   to   the   currently   available   cements   for   minimal  
invasive  augmentation  surgery  (PVP,  KB).  
1.4.2 Ceramic bone cements 
Ceramic   bone   substitutes   have   been   successfully   used   in   various   orthopedic   and  
cranio-­‐‑maxillofacial   applications.  Substitutes  are  available  pre-­‐‑shaped   (e.g.,   cylinders,  
blocks,  wedges)  to  precisely  fit  into  variably  shaped,  critical  size  bony  defects,  but  also  
as   granules   or   powder   for   injection   in   bone   augmentation   procedures.   Ceramics   are  
remodelled   and   integrated   into   the   surrounding   bone   while   acting   as   a   synthetic  
osteoconductive   scaffold,   thus   being   degraded   and   building   new   bone   concurrently.  
Therefore,  when  used  in  combination  with  internal  or  external  fixation  methods,  they  
are  able  to  fill  bone  voids  or  restore  fractures.    
1.4.2.1 Calcium phosphate based cements 
Calcium   phosphate   based,   synthetic   bone   grafts   have   osteointegrative   and  
ostoconductive   properties.   They   are   known   to   be   biocompatible   without   systemic  
toxicity   or   foreign   body   reactions.   Calcium   phosphate   cements   based   on  
hydroxyapatite,  β-­‐‑tricalcium  phosphate  and  mixtures   thereof  are  reportedly  bioactive  
and  osteoconductive.    
They  consist  of  two  components,  calcium  orthophosphate  (solid  phase)  and  a  liquid  
phase,   forming  a  paste,  which  hardens  through  dissolution  and  precipitation  without  
extensive   exothermal   heat   generation.   The   compressive   strength   of   the   hardened  
material   is  25-­‐‑45  MPa,  comparable  or  even  higher   than  that  of  cancellous  bone,  but  a  
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very   low   tensile   strength   (3-­‐‑5MPa)   limit   the   use   of   calcium   phosphate   cements   to  
virtually   non   load-­‐‑bearing   applications.   Low   mechanical   strength   in   shear,   bending  
and   tension   led   to   development   of   fiber   reinforced   calcium   phosphate   composites.  
Various   studies   have   demonstrated   improved   strength   using   different   bioresorbable  
fibers  for  reinforcement  (e.g.,  polyglactin  fibres  [87],  polypropylene  fibres  [88]).  Norian  
SRS   (DePuy   Synthes)   is   a   commercially   available,   fiber-­‐‑reinforced   bone   void   filler.   It  
consists   of   a   calcium   phosphate   powder,   bioresorbable   fibers   (lactide-­‐‑glycolide   co-­‐‑
polymer,  to  provide  an  increase  in  toughness  and  allow  the  material  to  be  drilled  and  
tapped)  and  a  liquid  component  to  increase  viscosity  leading  to  improved  mixing  and  
flow  properties.  Various  clinical  applications  show  favorite  outcomes  [45,89].  
Most   common   clinical   use   of   calcium   phosphate   bone   cements   and   composites   is  
filling   of   bone  defects   and   subchondral   voids   in  metaphyseal   fractures   (distal   radius  
[89],   proximal   humerus   [90],   calcaneus   [46],   tibial   plateau   [43]),   acting   thereby   as  
osteoconductive  scaffold  and  structural  support.    
1.4.2.2 Calcium sulfates-based cements 
Calcium  sulfate,  known  also  as  “plaster  of  Paris”  was  first  documented  being  used  by  
the  Arabs  in  the  10th  century  for  external  fracture  treatment,  surrounding  the  affected  
limb   with   a   tube   of   plaster.   In   1852   it   was   integrated   in   bandage   material   used  
externally   to   brace   the   fractured   limb.   In   1892   it   was   first   used   internally   for   the  
treatment  of  tuberculosis  osteomyelitis  in  long  bones  [91].    
Plaster   of   Paris   implanted   adjacent   to   periosteum   or   endosteum   act   as  
osteoconductive  matrix  for  vessel  ingrowth  and  cell  migration  [92],  degradates  fast  by  
dissolution  within   5-­‐‑7   weeks   [93].   In   comparison   to   cancellous   bone   it   has   a   higher  
compressive  strength,  but  a  lower  tensile  strength.  However,  because  in  vivo  it  softens  
and  cracks  when  exposed  to  moisture  and  degradates  fast,  it  lacks  extended  structural  
properties   and   therefore   should  only  be  used  as  bone  void   filler   in  non   load-­‐‑bearing  
applications  [40].    
Successful   non   load-­‐‑bearing   applications   include   filling   stable   cavity   defects  
resulting  from  curettage  of  benign  bone  tumors   [94],  metaphyseal   traumatic   fractures  
impacting  underlying  cancellous  bone  or  periprosthetic  bone  loss  [95,96].  
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1.5 Complications of augmentation procedures  
Although   augmentation   of   cancellous   bone   is   effective   to   enhance   fracture   stability,  
reduce  fracture  incidence  and  relief  pain,  its   indication  has  to  be  balanced  against  the  
potential   risk   for   various   complications.   Especially   PMMA   bone   cement   and  
composites  thereof,  used  for  medium  and  high  load-­‐‑bearing  applications  may  lead  to  
cement   leakage,   fat   embolism,   toxic   effects   and   thermal   damage.   In   vertebral  
augmentation   it   may   increase   the   risk   for   adjacent   fractures.   Complication   rate   and  
severity   are   related   to   cement   volume,   cement   viscosity   and   cement   distribution   as  
well  as  to  the  type  of  augmentation  procedure  and  the  anatomical  site.  
Cement  leakage  or  extravasation  into  joints,  the  fracture  site,  surrounding  tissue  or  
into  the  blood  system  is  one  of   the  most  common  complications,  which  could   lead  to  
severe  consequences.  
From  knowledge  gained  in  a  theoretical  and  experimental  model  used  by  Bohner  et  
al.,   the   authors   conducted   that   cement   extravasation   is   influenced   by   several  
parameters:  Bone  permeability,  bone  marrow  and  cement  viscosity,  bone  porosity  and  
pore  size,  size  of  injection  cavity,  diameter  of  extravasation  path,  and  injected  cement  
volume.  Among  all  these  parameters,  only  cement  viscosity  and  cement  volume  do  not  
depend  on  bone  structure   [61].  Seemingly  only  an   increase   in  cement  viscosity  and  a  
decrease  of  injected  cement  volume  [97]  are  parameters  under  control  of  the  surgeon  to  
reduce  the  risk  of  extravasation,  which  is  in  agreement  with  surgical  observations  [98].    
Breusch  et  al.  demonstrated  in  a  sheep  model  using  bilateral,  simultaneous  cement  
injection  under  pressure  into  femoral  heads  that  low  viscosity  cement  follows  the  path  
of   least   resistance   into   the   venous   system  before   deeper   cement   penetration   into   the  
cancellous   bone   can   occur   [62].   Cement   flow   into   the   venous   system   may   lead   to  
pulmonary  infarction  and  death  [74].  Contrary,  for  injections  of  high  viscosity  cement,  
an  improved  cement  penetration  was  observed,  eventually  leading  to  fat  embolism  by  
the  cement  forcing  bone  marrow  and  fat  cells  instead  into  the  blood  circulation  [62].    
While   the   maximum   PMMA   cement   volume   used   for   implant   augmentation   is  
rather   low   (0.5   mL   per   screw   up   2-­‐‑4   mL   total   if   more   screws   are   augmented),   the  
volumes  are  commonly  higher  for  vertebral  augmentation  and  void  filling  procedures  
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in  general  (3-­‐‑6  mL  per  lumbar  vertebra  up  to  25  mL  total).  Extravasation  of  cement  into  
the  blood  system  is  therefore  extremely  rare  during  implant  augmentation.  
  Nevertheless,   to   reduce   the   risk   of   cement   leakage   during   implant   augmentation  
into   the   joint,   fracture   gap   or   venous   system,   contrast   fluid   (0.5-­‐‑10   mL)   is   injected  
under  fluoroscopic  control  prior  to  cement  application.  If  the  contrast  fluid  stays  in  the  
injected   bone,   it   is  washed   out   using   saline   solution   (6-­‐‑10mL).  Only   if   no   leakage   of  
contrast   fluid   is   observed,   augmentation   should   be   performed.   If   cement   leakage  
occurs   the   injection   has   to   be   stopped   immediately.   Cement   leakage   into   the   joint  
always  requires  immediate  open  joint  surgery  to  remove  the  cement  from  the  joint.    
Many  studies  have  demonstrated   that   lower   infiltration  volumes  decrease   the   risk  
for   complications   such  as   cement   extravasation,   cement  or   fat   embolism  of   the   lungs  
and  fractures  of  adjacent  vertebrae  [99].    
Although,   cement   leakage   is   often   asymptomatic,   severe   consequences   may   exist  
[100]   and   depend   on   the   type   of   leakage.   Three   main   types   of   leakages   exist   for  
vertebral  augmentation  [101]:    
(1)  Leaks  through  a  cortical  defect  into  surrounding  tissue  are  relatively  unpredictable  
and  may  invade  areas  like  the  disc  space,  spinal  canal,  neural  foramen  or  even  leak  into  
surrounding  muscles.    
(2)  Leaks  into  the  segmental  vein  may  lead  to  respiratory  (pulmonary  embolism)  and  
cardiovascular  deterioration  [102,103].    
(3)  Leaks   into   the  basivertebral  veins   invade   the   spinal   canal   and  may   lead   to   spinal  
cord  or  nerve  root  compression,  or  rarely  to  pulmonary  embolism  [104,105].    
If  spinal  cord  or  nerve  root  compression  is  diagnosed  by  CT  and  comprises  severe  
neurological  deficiencies,  immediate  surgical  decompression  has  to  be  performed.    
Most  cases  of  pulmonary  cement  embolism  seem  to  be  without  clinical  symptoms,  
although   some   symptoms   like   chest   pain,   dyspnea,   acute   respiratory   distress  
syndrome  and  also  death  may  occur.  
Hulme   et   al.   indicated   that   leakage   in   surrounding   tissue   occurs   in   41%   of  
augmented   vertebrae,   with   2%   of   these   belonging   to   pulmonary   emboli   and   a   total  
occurrence   of   pulmonary   embolism   during   PVP   of   0.6%   [106].   These   numbers,  
however,  are  challenged  by  others  [100,101]  as  they  argue  that  omission  of  CTs  or  chest  
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radiographs   after   vertebroplasty   on   asymptomatic   human   patients   may   lead   to   an  
underestimation   of   cement   leakage   and   pulmonary   emboli   occurrence   secondary   to  
vertebroplasty.  
Embolization   of   bone   marrow   and   fat   occurs   in   a   large   proportion   of   patients  
undergoing   major   orthopedic   surgery   such   as   total   hip   [107]   and   knee   [108]  
arthroplasty,   intramedullary   nailing   for   stabilization   of   fractured   long   bones   [109],  
instrumented   spine   surgery   [110],   PVP   and   BKB   [111,112].   However,   it   remains  
asymptomatic  in  most  patients.  
In  case  of  vertebral  augmentation  procedures  (PVP/BKB)  it  is  hypothesized  that  the  
injection   of   PMMA   bone   cement   causes   an   increase   of   the   intramedullary   pressure  
leading   to   a   dislodge   of   bone   marrow   and   fat   cells.   These   follow   the   path   of   least  
resistance  into  the  venous  circulation  [111].  This  may  occur  with  and  without  evidence  
of   additional   cement   leakage.   Subsequently,   the   capillaries   of   the   end   organs   are  
obstructed  mechanically.  If  the  emboli  are  flushed  out  into  the  pulmonary  vasculature,  
a  biochemical  and  inflammatory  cascade  is  initiated  including  a  reflex  vasoconstriction  
of  the  pulmonary  vessels,  a  release  of  vasoactive  mediators  (endothelin)  and  activated  
coagulation.  Actual  cement  embolism  may  result   in  an  allergic  reaction  to  the  foreign  
material.   The   inflammatory   cascade   may   prompt   an   increase   of   pulmonary   arterial  
pressure   [113,114].   If   persistent,   the   high   pulmonary   arterial   pressure   will   cause   a  
clinically   evident   pulmonary   embolism   with   severe   cardiovascular   effects,   such   as  
acute   heart   failure   with   a   decrease   in   cardiac   output   causing   systemic   arterial  
hypotension.   Increased   dead   space   ventilation   will   cause   ventilation-­‐‑perfusion  
mismatch  ultimately  leading  to  hypercapnia  and  hypoxemia. While in  most  cases  the  
cardiovascular  effects  are  mild  and  transient,  cardiac  arrest  and  death  have  also  been  
reported  [111,112,115]. 
The   exothermic   polymerization   reaction   of   PMMA   cement   initiates   high  
temperatures  up  to  70°C  in  the  center  of  the  material  [116].  This  likely  causes  thermal  
damage   and   ultimately   cell   necrosis   of   osteocytes   and   chondrocytes   [8,81,82].   The  
resulting   disturbance   of   subchondral   bone   supply   may   trigger   joint   cartilage  
degeneration   [8,117].   Therefore,   subchondral   cement   injection   should   maintain   a  
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minimal   distance   to   the   joint   surface   of   6-­‐‑10   mm.   The   injected   volume   should   be  
reduced  to  a  minimum  needed  for  sufficient  stabilization  of  the  bone  [97].    
In   addition   to   thermal   damage  due   to   the   exothermal   chemical   reaction   of   curing  
PMMA,  many  in  vitro  studies  have  shown  severe  local  or  systemic  cytotoxicity  (tissue  
irritation,   inflammation)   to   the   liquid  monomer   [118].  Local   toxic   tissue   reactions  are  
reported   such   as   fibrous   tissue   formation   at   the   interface   between   bone   and   PMMA  
[119],   especially   if   injected   early   in   of   the   polymerization   phase,   with   a   still   higher  
percentage  of  residual,  not  yet  bonded,   toxic  monomer.  Systemic  toxic  reactions  (e.g.,  
hypoxia,  hypotension,  anaphylaxis,  death)  due   to  extravasation  of   small  quantities  of  
unbound   liquid  monomer   into   the   venous   circulation   [120]   have   been   reported   and  
may  affect  lungs,  kidneys  and  the  liver.  Therefore,  research  efforts  ought  to  be  invested  
to  develop  new   composites   of   PMMA  bone   cements  with   enhanced  biocompatibility  
and  reduced  toxicity[121].    
Several  studies  have  shown  that  following  a  first  vertebral  compression  fracture  the  
risk  of  additional  fractures  is  increased,  particularly  in  adjacent  vertebrae  [80,106,122].  
A   retrospective   study  of  Kulçsar   et   al.  estimated  “that  almost   every   fifth  patient   is   at  
risk  for  developing  a  new  fracture  after  PVP,  but  only  every  tenth  fracture  is  likely  to  
be   related   to   the   previous   vertebral   augmentation.   Female   patients   with   severe  
osteoporosis  are  probably  facing  the  highest  risk  for  developing  new  fractures”  [123].    
Baroud   et   al.   demonstrated   in   ex   vivo   studies   an   increase   in   stiffness   of   the  
augmented   vertebrae   of   up   to   36   times  when   compared   to   normal   spinal   cancellous  
bone   [99,124].   The   cement   acts   in   augmented   vertebrae   like   an   “upright   pillar”,  
reducing  the  physiologic  inward  bulging  of  the  endplates.  This  increases  the  pressure  
measured  in  the  adjacent  intervertebral  disc  by  approximately  19%.  The  induced  load  
shift   to   the  adjacent  vertebra  may  cause  an   increased  risk  of   fracture  and  possibly,   in  
the   long   run   degenerative   changes.   The   stiffness   of   the   augmented   vertebra   is  
unnecessarily   high.   The   authors   hypothesized   that   injecting   a   reduced   amount   of  
PMMA  cement  or  using  a  softer  augmentation  material  would  still  provide  sufficient  
augmentation   strength,   but   the   lower   stiffness  would   significantly   reduce   the   risk   of  
adjacent  vertebral  fractures  [99,125].    
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Barr   et   al.   commented   in   2001   that   kyphotic   deformity   caused   by   osteoporosis  
results   in   increased   stress   on   adjacent   vertebrae   and   thus   puts   them   at   high   risk   for  
additional  fractures.  Hence,  in  these  cases  prophylactic  augmentation  is  indicated  [48].  
A   change   in   local   biomechanics   may   be   provoked   by   either   progressive   spine  
deformity,   by   previous   vertebroplasties   [57,79,80],   by   natural   progression   of   the  
underlying  disease  (osteoporosis,  metastasis  induced  osteolysis)  or  by  a  combination  of  
the   above.   Whether   that   increases   the   fracture   risk   of   adjacent   or   distant   vertebrae  
remains  unclear.  
1.6 Animal models in literature 
Major   research   efforts   are   under   way   to   improve   the   currently   available   treatment  
options   for   osteoporosis   and   to   develop   new   strategies   for   the   surgical   treatment   of  
fragility   fractures   and   implant   loosening.   They   include   new   implants   for  
osteosynthesis  with  augmentation  options,  as  well  as  biological  approaches   including  
new   biocompatible   materials.   Although   new   implants   and   biomaterials   could   be  
mechanically  tested  in  fresh  cadaveric  specimen,  in  vivo  experiments  are  required  for  
proof  of  principle  and  safety   reasons.  Therefore,   animal  models  are   important   to   test  
new  strategies.    
Davidson   et   al.   defined   already   in   1987   that   “an   appropriate   animal   model   for  
research   should   be   based   on   the   following   considerations:   1)   appropriateness   as   an  
analog,   2)   transferability   of   information,   3)   genetic   uniformity   of   organisms   where  
applicable,  4)  background  knowledge  of  biological  properties,  5)  cost  and  availability,  
6)  generalizability  of  the  results,  7)  ease  and  adaptability  to  experimental  manipulation,  
8)   ecological   considerations,   and   9)   ethical   and   societal   implications”   [126].   Animal  
models  used  for  research  of  human  diseases  meet  some,  but  certainly  not  all  of   these  
criteria.    
Rodents,  especially  mice  and  rats,  are  widely  used  as  animal  models  for  research  of  
osteoporosis   in   humans.  Numerous   genetically  well-­‐‑characterized  mouse   strains   and  
transgenic-­‐‑mice   with   deficiencies   in   bone   metabolism   (e.g.,   knock-­‐‑out   mice)   are  
available  and  used   for   studying   the  genetic   contribution   to  peak  bone  mass  and  age-­‐‑
related   bone   loss   [127].   Therefore,   the   mouse   seems   to   be   a   good   model   for   basic  
research  of  age-­‐‑,  disuse-­‐‑,  or  postmenopausal-­‐‑related  osteoporosis.    
Introduction  
20  
Rats,  as  well  as  mice,  have  proven  to  provide  excellent  models  to  study  etiology  of  
osteoporosis  including  pathophysiological  changes  of  the  skeleton  (e.g.,  bone  fragility),  
histomorphometric   changes   and   the  validity  of   biochemical  markers   for   osteoporosis  
[128].  Mice  are  small-­‐‑sized  and  inexpensive  to  purchase  and  maintain.  They  also  grow  
rapidly   with   a   relatively   short   lifespan,   which   enables   studying   of   age-­‐‑related   bone  
loss.  Mice  also  have  well-­‐‑characterized  skeletal  bone  parameters  (e.g.,  BMD,  trabecular  
thickness)   [129].   Rodents   do   not   experience   a   natural   menopause,   as   humans   do.  
Therefore,   the   ovariectomized,   skeletally   mature   rat   is   widely   used   as   a   model   for  
postmenopausal  osteoporosis  in  humans  and  has  been  validated  as  a  clinically  relevant  
model  for  human  postmenopausal  bone  loss  [130-­‐‑132].  Estrogen  deficiencies  using  an  
estrogen  receptor  antagonist  induced  similar  loss  of  cancellous  and  endocortical  bone,  
but  the  changes  were  reversible  when  medication  was  ceased  [133].  Other  models  have  
been   used   to   study   the   etiology   of   disuse   osteoporosis   induced   by   lack   of   physical  
activity,  as  well  as  the  efficacy  of  potential  interventions.  As  animal  models  for  disuse  
osteoporosis   unloading   a   limb   was   forced   using   different   methods   (e.g.,   unilateral  
sciatic   nerve   section,   tenotomy,   unilateral   limb   casting,   internal   or   external   joint  
fixation  and  spaceflight)  [134-­‐‑136].  These  methods  led  to  similar  skeletal  changes  with  
significant  reduction  of  mineralization  and  changes  in  histomorphometric  parameters.  
The   induced   changes   towards   osteoporosis,   however,   are   related   primarily   to  
unloading   of   bone   and   thus   are   observed   locally,   but   never   systemically.   Alcohol-­‐‑
dependent   rats   are   used   to   study   etiology   and   severity   of   alcohol-­‐‑induced   bone   loss  
[137].    
Contrasting   advantages   of   using   rats   and   mice,   there   are   also   limitations   and  
disadvantages   to   their   use.   The   small   blood   volume   of   rodents   limits   the   amount   of  
sampling  for  multiple  biochemical  measurements.  Rats  have  a  different  bone  structure  
than  humans  with  no  Haversian  system  in  the  cortical  bone  and  no  remodeling  via  the  
basic   multicellular   unit   in   trabecular   bone   [138].   The   small   size   and   total   overall  
amount  of  bone  is  another  limiting  factor.  Resulting  in  difficulties  to  harvest  adequate  
sample  sizes  for  biomechanical  testing  and  limitations  for  surgical  procedures  such  as  
fracture   fixation.  Trabecular   thickness   and   separation  both   are   three   times   smaller   in  
comparison   to   humans.   These   obvious   differences   in   the   trabecular   bone   structure  
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reduce   the   comparability  of   rodent  osteoporotic  bone   to  human  osteoporotic  bone  as  
the   trabecular  structure  plays   the  primary  role   in   fragility   fractures.  The   translational  
problem  is  further  exacerbated  because  trabecular  bone  mass  represents  more  than  half  
of   total   bone  mass   in   the  proximal   femur  and   lumbar  vertebrae,   the   two  bones  most  
frequently  affected  by  osteoporotic  fractures.    
Therefore,   large  animals  such  as  sheep,  pigs,  goats,  calves,  and  dogs  may  be  more  
suitable   to   test   new   implants   or   biomaterials   evaluated   for   osteoporosis   treatment   in  
humans.  Although   some   large   animals   show  a  decrease   in  BMD  due   to   ovariectomy  
induced   osteopenia,   the   structure   and   BMD   of   osteoporotic   human   vertebral   bodies  
seems  unique.  A   study  of  Aerssens   et   al.   [139]   found  marked   interspecies  differences  
between  healthy   human,   dog,   pig,   cow,   and   sheep   lumbar   vertebrae   regarding   bone  
composition,   bone   density,   and   bone   mechanical   competence.   Indeed,   human  
vertebrae  reveal  much  lower  values  for  bone  mineral  content  and  density  compared  to  
that   of   the  other   species.  The   study   conducted   that  dogs  have   the  most   similar  bone  
structure   compared   to   humans,   but   porcine   bone   is   most   similar   in   BMD   and   bone  
mineral   content   (BMC)   when   compared   to   human   bone.   Nevertheless,   possible  
differences   in   bone   loading   with   the   quadruped   gait   of   animals   in   comparison   to  
humans  should  be  investigated  and  taken  into  account.    
For   many   years,   dogs   have   been   used   for   studies   on   the   human   skeleton   (e.g.,  
fracture   healing,   effects   of   immobilization,   long-­‐‑term   effects   of   bone-­‐‑active   agents,  
allografts)   as   well   as   for   studies   on   bone   ingrowth   and   joint   replacement   [140,141].  
However,  due  to  a  higher  bone-­‐‑remodeling  rate  in  dogs  compared  to  humans,  results  
may   not   be   transferable   [140].   Ovariectomy-­‐‑induced   osteopenia   models   for  
osteoporosis  in  dogs  are  not  suitable,  because  dogs  do  not  develop  estrogen  deficiency-­‐‑
related   bone   loss.   This   may   be   explained   by   the   infrequent   estrus   cycle   of   dogs  
resulting   in   extremely   low   estrogen   levels   throughout   most   of   the   year   [142].   In  
addition  to  the  above  limitation,  the  use  of  dogs  in  medical  research  is  further  hindered  
by  the  rise  in  negative  perception  and  increasing  ethical  concerns.  
In   that   regard,   farm   animals   (e.g.   sheep,   pigs,   goats)   are   preferable   because   of   a  
higher   public   acceptance.   Indeed,   the   latter   models   may   be   used   to   study  
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postmenopausal   osteoporosis,   fragility   fractures,   as   well   as   new   treatment   options  
including  surgical  techniques  and  biomaterials.  
Over  the  last  decades,  an  increasing  number  of  sheep  has  been  used  for  orthopedic  
research  [143].  As  farm  and  flock  animals,  they  suffer  the  least  stress  when  housed  in  
groups  of  two  or  more  animals,  which  makes  handling  easier  and  reduces  costs  [144].  
In   comparison   to   pigs,   sheep   are   usually   docile   and   compliant.   They   show   a   high  
acceptance   for   bandages   and   suspension   systems.   Due   to   their   comparable   size   to  
humans,   implants   and   surgical   equipment   for   human   use   does   not   need   to   be  
downsized  before  testing.  Therefore,  various  animal  models  using  mature  sheep  have  
been  successfully  established  by  our  group  for  studying  orthopedic  research  questions  
in  different   anatomical   locations.   Some  examples   are:   aseptic   loosening  model   of  hip  
prosthesis   [145],   drill   hole   model   for   biocompatibility   testing   of   biomaterials   in  
cancellous  bone  [146],  pelvic  model  for  testing  of  osseointegration  and  biocompatibility  
of  different   implants   [147,148],   tibiaosteotomy  models   for   testing  new  biomaterials  or  
newly  developed  implants  [149],  impingement  model  in  the  hip  [150],  or  a  chronically  
retracted  rotator  cuff  model  [151,152].    
Other   research   groups   have   reported   using   the   sheep   as   a   suitable   model   for  
research  of  osteoporosis.  Ovariectomy  [153],  glucocorticoid  treatment  [154],  and  highly  
anionic  diet  inducing  metabolic  acidosis  [155]  have  been  used  alone  or  in  combination  
[156-­‐‑159]   to   induce   bone   loss   in   sheep.   Different   studies   have   demonstrated   that  
ovariectomy   alone  may   not   be   sufficient   to   provoke   perceptible   bone   loss   [154].   The  
BMD  even  may  return   to  baseline  after  an   initial  decrease   including  a  rebound  effect  
[160].   However,   the   combination   of   ovarioectomy   followed   by   six   months   of  
glucocorticoid   treatment   has   produced   a   significant   loss   of   trabecular   bone   in   the  
proximal   tibia.   Compared   to   control   animals   a   significantly   reduced   bone   mineral  
density,   bone   volume,   and   elastic   modulus   was   assessed   using   densitometry,  
histomorphometry,   and   biomechanical   testing,   respectively.   Even   six   months   later  
without   glucocorticoid   treatment,   the   changes   in   trabecular   bone   were   still   similar  
[154].   In   a   study   of  Ding   et   al.   [159]   significant   loss   of   cancellous   bone  was   induced  
using  the  combination  of  glucocorticoid  treatment  and  deficient  diet  (i.e.,  low  calcium  
and   phosphorus).   After   seven   months,   significant   changes   in   microarchitecture   and  
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mechanical   properties   in   the   lumbar   vertebrae,   distal   femur   and  proximal   tibia  were  
detected.   However,   three   months   later   without   glucocorticoids   and   diet  
microarchitecture   and   bone   strength   have   recovered.  A   combination   of   ovariectomy,  
glucocorticoid   treatment   and   calcium/vitamin   D-­‐‑restricted   diet   seems   an   effective  
method   to   induce  and  retain  a  decrease  of  bone  mineral  density  and  deterioration  of  
trabecular  bone  [156].  However,  for  both  the  glucocorticoid  treatment  (adverse  effects,  
especially  for  immune  system)  and  for  the  deficiency  diet,  ethical  considerations  need  
to   be   taken   into   account   when   using   these   models.   In   addition,   this   combined  
treatment  does  not  mimic  the  pathogenesis  of  osteoporosis  in  postmenopausal  women,  
because   glucocorticoid   induced   osteopenia   presents   with   a   different   underlying   cell  
mechanism.    
Another   important   fact   is   that   seasonal   changes   of   bone   mass   are   a   potential  
variable  when  using  sheep  in  studies  of  osteopenia  [161,162]  and,  like  in  dogs,  related  
to  the  periods  of  anestrus,  which  in  sheep  is  linked  to  the  environmental  photoperiod.  
Some   breeds   can   continue   their   cycle   almost   all   year-­‐‑round   and   therefore   are   more  
sensitive  to  estrogen  deficiency  (e.g.  merino  sheep).  
As   already   discussed   in   our   previous   publications,   good   animal   models   for  
vertebral  augmentation  are  rare  [163,164].  Sheep  has  been  mainly  used  in  acute  studies  
for  augmentation  in  the  lumbar  spine  for  research  of  cardiovascular  complications  such  
as   pulmonary   fat   [165]   or   cement   [114]   embolism.   Using   percutaneous   [166],  
retroperitoneal   [167,168]   and   open   approaches   [165,169]   to   the   lumbar   vertebrae,  
pulmonary   complications   similar   to   those   seen   in   humans   have   been   described   in  
vertebroplasty  studies   in  sheep  (immediate  sacrifice  on  the   table  after  augmentation).  
Turner  et  al.  reported  using  aged-­‐‑ovariectomized  ewes  for  vertebroplasty  of  the  lumbar  
spine   using   histological   evaluation   for   examination   of   osteoconductivity   and  
remodeling   properties   of   the   injected   cement   [144].   They   indicated   that   a   serious  
complication  and  major  limitation  of  this  model  is  inadvertent  penetration  of  the  floor  
of  the  spinal  canal  with  subsequent  leakage  of  material  into  the  dural  space  even  under  
fluoroscopic  guidance  [170].  In  fact,  this  complication  may  lead  to  paraplegia  and  early  
termination  of  the  experiment,  although  mostly  these  complications  are  never  reported  
in  the  literature  and  only  admitted  in  personal  communications.  An  adequate  surgical  
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access   to   the   ovine   vertebral   body   of   the   thoracic   and   lumbar   spine   including  
subsequent   injection   of   augmentation   material   in   a   standardized   and   reproducible  
fashion  is  very  difficult  and  almost  impossible  [171-­‐‑173].  The  limiting  factors  compared  
to   the   human   spine   are   the   large  muscle  mass   in   this   area,   the   oversized   transverse  
processes,   the  different  orientation  of   the   facet   joints  and,  mainly,   the  ovine  vertebral  
body   size   and   shape   (slim,   trapezoid),   which   is   quite   different   to   that   of   humans  
(round,  solid,  almost  rectangular).    
1.7 Rationale of the study and specific aims of the project 
This   PhD   project   was   designed   to   develop   new   in   vivo   animal   models   for   the  
augmentation   of   cancellous   bone   in   a   highly   standardized   and   reproducible  manner  
for  the  evaluation  of  new  biomimetic  materials.  Using  these  in  vivo  models,  biomaterial  
composites  were  tested  for  their  efficacy  to  induce  new  bone  formation  and,  therefore,  
strengthen   the   cancellous   bone.   The   material’s   biocompatibility   and   degradation  
properties  were  equally  evaluated.    
To   the   best   of   our   knowledge,   to   date   there   is   still   no   adequate,   bioactive   and  
resorbable   material   for   prophylactic   augmentation   available.   Such   material   would  
require   the   ability   to   induce   new   bone   formation   and   normalize   pathologically  
changed  trabecular  structure  of  osteoporotic  bones  at  risk  for  fracture.  Research  efforts  
should  be  made  to  develop  adequate  animal  models  for  testing  of  existing  and  newly  
developed  augmentation  materials.  
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2 Bone Augmentation for Cancellous Bone- Development of a New 
Animal Model 
2.1 Aim of the study 
This   study   aimed   at   developing   a   simple   reproducible   and   standardized   bone  
augmentation  model  in  sheep.  The  model  should  preferably  reproduce  the  pulmonary  
complications   seen   in   human   and   ovine   vertebroplasty.   In   addition,   a   standardized  
and  reproducible  evaluation  method  to  compare  results  of  different  studies  should  be  
established.   We   hypothesized   that   a   tibia   and   femur   augmentation   model   in   sheep  
would  fulfill  all  these  above  needs.  
2.2 Main conclusions 
The   tibia   and   femur   augmentation   model   has   proven   to   be   suitable   for   screening  
studies   of   new   biomaterials   intended   for   trabecular   bone   augmentation.   It   enabled  
analysis  of  biodegradable,  biocompatible  and  osteoconductive  material  properties.  The  
model  also  has  proven  to  be  adequate  for  the  study  of  the  sequelae  of  material  leakage  
into  the  circulation,  i.e.  pulmonary  embolism  with  associated  cardiovascular  changes.  
Overall,  we  consider  the  tibia  and  femur  augmentation  model  to  be  safe  when  used  
by  the  experienced  surgeon,  resulting  in  reduced  animal  suffering  and  suitable  to  serve  
well  for  testing  of  bone  inducing  or  enhancing  materials  for  vertebroplasty.  
2.3 Contribution to this publication 
I   was   profoundly   involved   in   all   aspects   of   the   study   including   performing   the  
surgeries,  outcomes,  evaluation  and  writing  the  manuscript.    
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Abstract
Background: Reproducible and suitable animal models are required for in vivo experiments to investigate new
biodegradable and osteoinductive biomaterials for augmentation of bones at risk for osteoporotic fractures. Sheep
have especially been used as a model for the human spine due to their size and similar bone metabolism.
However, although sheep and human vertebral bodies have similar biomechanical characteristics, the shape of the
vertebral bodies, the size of the transverse processes, and the different orientation of the facet joints of sheep are
quite different from those of humans making the surgical approach complicated and unpredictable. Therefore, an
adequate and safe animal model for bone augmentation was developed using a standardized femoral and tibia
augmentation site in sheep.
Methods: The cancellous bone of the distal femur and proximal tibia were chosen as injection sites with the
surgical approach via the medial aspects of the femoral condyle and proximal tibia metaphysis (n = 4 injection
sites). For reproducible drilling and injection in a given direction and length, a custom-made c-shaped aiming
device was designed. Exact positioning of the aiming device and needle positioning within the intertrabecular
space of the intact bone could be validated in a predictable and standardized fashion using fluoroscopy. After
sacrifice, bone cylinders (∅ 32 mm) were harvested throughout the tibia and femur by means of a diamond-coated
core drill, which was especially developed to harvest the injected bone area exactly. Thereafter, the extracted bone
cylinders were processed as non-decalcified specimens for μCT analysis, histomorphometry, histology, and
fluorescence evaluation.
Results: The aiming device could be easily placed in 63 sheep and assured a reproducible, standardized injection
area. In four sheep, cardiovascular complications occurred during surgery and pulmonary embolism was detected
by computed tomography post surgery in all of these animals. The harvesting and evaluative methods assured a
standardized analysis of all samples.
Conclusions: This experimental animal model provides an excellent basis for testing new biomaterials for their
suitability as bone augmentation materials. Concomitantly, similar cardiovascular changes occur during
vertebroplasties as in humans, thus making it a suitable animal model for studies related to vertebroplasty.
Background
Handling and injective properties of new biomaterials
for vertebral bone augmentation can be tested in fresh
cadaveric specimens, but in vivo experiments are re-
quired for proof of principle and safety reasons as the
presence of blood flow could significantly alter the risk
of leakage. Animals such as sheep, pigs, goats, calves,
and dogs have been reported as models for several med-
ical problems associated with the human spine [1], in-
cluding bone defects [2] and kyphoplasty [3] in the
lumbar area, although with a high complication rate. For
vertebroplasty in sheep, mostly acute studies (euthanasia
during anesthesia without recovery) were reported with
the focus on cardiovascular complications such as
pulmonary embolus formation. Cement leakage was
followed within the systemic circulation, but not
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documented within the spinal canal as reported also in
humans [4].
Pulmonary complications similar to those seen in
humans have been described in vertebroplasty studies in
sheep, where percutaneous [5], retroperitoneal [6,7] and
open approaches [8-11] to the lumbar vertebrae were
used. However, the minimally invasive surgical technique
of percutaneous augmentation as commonly used for
treatment of symptomatic vertebral compression frac-
tures in humans, occurring secondary to osteoporosis or
neoplasia [12-19], proved to be difficult to reproduce in
the lumbar vertebrae of sheep. This is primarily due to
the shape of the ovine vertebral body which is quite dif-
ferent and much more difficult to surgically access than
in humans [3,20,21]. Even the standard surgical open ap-
proach to the lumbar area is complicated due to the
large muscle mass in this area, the size of the transverse
processes, the different orientation of the facet joints
and mainly the slim, hour-glass shaped vertebral bodies.
Even under fluoroscopic guidance, inadvertent penetra-
tion of the floor of the spinal canal with subsequent
leakage of material into the dural space are serious com-
plications and major limitations of this model [22]. In
fact, this complication often leads to paraplegia and early
termination of the experiment, although mostly these
complications are never reported in the literature and
only admitted in personal communications. A high per-
centage of the animals have to be euthanized immedi-
ately after recovery due to severe pain and clinical
symptoms often require immediate termination of the
experiments.
Apart from animal welfare reasons (suffering, numbers
of animals used in the experiment), increased costs, high
efforts, and unpredictable outcome necessitate a novel,
simply reproducible and standardized animal model in
sheep. In addition, the animal model preferably should
reproduce the pulmonary complications ranging from
no clinical signs to severe cardiac distress symptoms as
seen in human and ovine vertebroplasty [10,16]. More-
over, a standardized and reproducible evaluation method
to compare results of different studies should be avail-
able. We hypothesized that a femoral and tibial bone
augmentation model in sheep would fulfill all these
criteria.
Methods
Study design and experimental animals
For this novel experimental animal model the relatively
dense cancellous bone of the distal femoral condyle and
proximal tibia metaphysis was chosen as location for
the application of radiopaque augmentation materials. A
customized aiming device was developed that allowed
repeatable, safe and standardized injections under
fluoroscopic guidance.
For proof of this animal model 63 adult, female, Swiss
alpine sheep with an average age of 2.7 years (2–5 years)
and a body mass of 70.4 kg (49–99 kg) were used from
consecutive studies focusing on different biomaterial for-
mulations for augmentation (see Table 1). In all sheep,
the same material was injected into the femoral condyle
and proximal tibia of the same limb. Various radiopaque
formulations of biomimetic materials based on a fibrin-
scaffold were tested in comparison to sham controls.
Since this manuscript is dedicated to the description of
the animal model including evaluative procedures, the
details of materials and results of bone enhancement will
be published elsewhere (publication in preparation).
Overall, 12 groups of materials were tested with 5–7 ani-
mals/group (Table 1). As controls sham surgeries were
conducted in 5 sheep.
Due to the low morbidity and invasiveness of the sur-
gical procedure, both hind limbs could be chosen,
resulting in a total of four augmentation sites per sheep
to inject material (n = 252 augmentation sites). For ani-
mal protection and welfare issues, a vertebral augmenta-
tion group as comparison to the new animal model was
omitted due to the expected complications. (In a previ-
ous study in collaboration with an associated research
group using an open and retroperitoneal approach to
the lumbar spine, >80% of the animals had to be eutha-
nized due to complications such as leakage into the
spinal canal and fracture of the vertebral body).
All experiments were conducted according to the
Swiss regulations of Animal Welfare and permission was
granted by the local federal authorities (application # 7/
2008).
The animals were acclimatized to the new environ-
ment approximately 2 weeks before surgery. A pre-
anesthetic examination was performed including general
clinical examination, hematology and chemscreen. Food
was withdrawn 24 h before induction of anesthesia,
while water was available ad libitum.
Animal model
Instruments/equipment
In addition to the routinely used surgical instruments, a
custom-made-aiming device was developed in order to
increase reproducibility of surgical access and to
standardize the injected area. The C-shaped aiming de-
vice allows exact positioning at the medial and lateral
aspects of the tibia or femur including drilling in a given
direction and at a predictable length (Figure 1). The
aiming device consisted of two arms. The distance be-
tween the arms could be adjusted in order to fit the
lateromedial axis of the stifle. A sharp tip is mounted ax-
ially on one arm while a concentric outer tube with
sharp teeth is positioned on the other arm. The aiming
device has to be placed with the tube for the drill hole at
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the medial aspect and the sharp tip fixed on the lateral as-
pect of the tibia or femur (Figure 2a). This positioning of
the aiming device allows the insertion of the drill and ul-
timately the needle relatively parallel to the articular surface
of the femoro-tibial joint. With the concentric tube and the
distal sharp tip being in line, the suggested insertion trajec-
tory for the needle can be validated using fluoroscopy in
mediolateral and craniocaudal view (Figure 2b).
For the injection of augmentation material, a 10G
(3.2 mm diameter) 100 mm-long special vertebroplasty
needle (1394–1010, Optimed Medizinische Instrumente
GmbH, Ettlingen, Germany) and an Optimed CementoRE
gun (1392–0000, Optimed Medizinische Instrumente
GmbH, Ettlingen, Germany) were used. The vertebroplasty
needle consisted of three parts, needle, handle, and stylet
(Figure 1).
Table 1 Group distribution and CT analysis
Group Number of animals Material CT Clinical signs of pulmonary embolism
1 6 FS +MP1 + CA, with/without BM4 1 1
2 7 FS + CA, with/without BM4
3 5 control/sham 2
4 6 FS +MP2 + CA, with/without BM4
5 6 FS +MP2 + CA, with/without BM4
6 6 FS + CA, with/without BM4
7 5 FS + MP2 + BM1 5
8 5 FS + MP2 + BM2 4
9 5 FS + MP2 + BM3 4 1
10 2 FS + MP2 + BM4
11 5 FS + MP2 + BM5 2 1
12 5 FS + MP2 + BM6 1 1
Legend:
FS: Fibrin-scaffold.
MP1 or 2: Mineral powder 1 or 2.
CA: Contrast agent.
BM1-6: Biomimetic agent concentration 1-6.
with/without: One leg with and one leg without BM4.
This table shows the group distribution of all animals including the numbers of CT’s performed in each treatment group as well as the numbers of animals with
cardiovascular complications occurring during surgery.
Figure 1 C-shaped aiming device. This photograph shows the c-shaped aiming device consisting of two adjustable arms with a mountable
concentric outer tube with sharp teeth (a) and a mountable sharp tip (b) for device fixation. For application of biomaterial, a drill (c) and
subsequently a 10G-vertebroplasty needle (needle (d), handle (e), and stylet (f)) were applied through the arm with the concentric tube (a).
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Anesthesia and analgesia
Animals were premedicated intramuscularly with
buprenorphine (Temgesic®, 0.01 mg/kg, Essex Chemie
AG, Lucerne, Switzerland) and xylazine (Rompun® 2%,
0.1 mg/kg im, Streuli Pharma, Uznach, Switzerland).
After approximately 30 minutes, a catheter (Vygonyle S®
G14, Vygon GmbH, Aachen, Germany) was placed into
one jugular vein and prophylactic antibiotics (Penicillin
Natrium® 35′000 IU/kg i.v.; G. Streuli Pharma, Uznach
Switzerland; gentamicin, Vetagent®, 4 mg/kg i.v.,
Veterinaria AG, Zurich, Switzerland) as well as a pre-
emptive analgesic (Rimadyl®, 4 mg/kg i.v.; Pfizer SA,
Zurich, Switzerland) were given intravenously. A
booster for tetanus (tetanus serum Intervet, 3000 IU/
sheep s.c.; Veterinaria AG, Zurich, Switzerland) was
administered subcutaneously. Anesthesia was induced
with diazepam (Valium®, 0.1 mg/kg i.v., Roche Pharma
AG, Rheinach, Switzerland), ketamine (Narketan 10®,
2 mg/kg i.v., Vetoquinol AG, Belp-Bern, Switzerland)
and propofol (Propofol®, 0.4-2 mg/kg iv, Fresenius
Kabi, Stans, Switzerland) administered to effect.
After laryngeal desensitization with lidocain spray
(Xylocaine Spray 10%, 3 pumps of 0.1 mL, Astra
Zeneca AG, Zug, Switzerland), the trachea was
intubated and correct placement was confirmed by ex-
pired carbon dioxide monitoring (FetCO2). Anesthesia
was maintained with a balanced anesthetic protocol
employing administration of isoflurane (1-2%vol) in
oxygen via an adult F-circuit (circle system, Intersurgical,
Berkshire, UK) and a constant rate infusion of propofol
(Propofol®, 0.5-1 mg/kg/h, Fresenius Kabi, Stans,
Switzerland). All animals received intravenous fluids
throughout the procedure (Ringer solution, 10 mg/kg/
h). Cardiovascular monitoring parameters included
electrocardiogram (ECG), heart rate, pulse rate and
invasively measured blood pressures (systolic, mean
and diastolic arterial) via an arterial catheter in an
auricular artery.
Surgical procedure
The anesthetized sheep were placed in dorsal recum-
bency tilted at a 30° angle to the non operated side, with
the hind limb slightly flexed and fixed at the surgery
table. For the second leg repositioning was required.
Aseptic preparation of the surgical field was performed
routinely.
Two small incisions (1 cm) were performed at the
medial aspect of the femoral condyle (directly above the
femoral epicondyle) and at the metaphysis of the prox-
imal tibia (at the distal end of the collateral ligament).
Soft tissue was dissected down to the bone and the
aiming device was placed with the tube for the drill hole
at the medial aspect and the sharp tip fixed on the lat-
eral aspect of the tibia or femur (Figure 2a). For fixation
of the sharp tip on the lateral side only two stab
incisions of the skin were needed, at the same level as
the medial ones. Bleeding was controlled using an
electrocautery.
Using fluoroscopy in two projection planes (mediolateral
and craniocaudal), the right position of the aiming device
and subsequent needle positioning could be validated and
inaccurate injections avoided.
A drill hole with a diameter of 2.7 mm was created
and followed by placing the special vertebroplasty needle
with the tip ending in the trabecular portion of the fem-
oral condyle (in parallel direction to the stifle joint sur-
face) or proximal tibial bone (in slightly oblique
direction to the fibula head).
The material injections were done in multiple steps
under fluoroscopic guidance. Needle filling with bio-
mimetic material was done slowly with the aid of the
Optimed CementoRE gun (Figure 3). Subsequently, the
gun was removed and a stylet was used to push the ma-
terial through the needle into the bone, so as to provide
exact quantities of injectate. If necessary a hammer was
used to push the stylet and the material into the bone.
The filling-clearing procedure was repeated three or four
a b 
Figure 2 Correct placement of the aiming device. The aiming device was placed with the tube for the needle at the medial aspect and the
sharp tip fixed on the lateral aspect of the tibia (a). Fluoroscopy pictures were used to validate correct placement of aiming device and needle as
well as subsequent material injections (b).
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times, until a target of 2.7 mL was distributed within the
intertrabecular space. Using fluoroscopy, leakage of the
material into a vessel and thrombus formation was
recorded and the amount of that material was estimated
and documented.
Sham operations consisted of drilling and placing the
needle as described above. The stylet was then inserted
and removed three times without material injection.
At completion of the injection procedure, the
vertebroplasty needle and the aiming device were re-
moved and the insertion point was closed with a
3.5 mm diameter self-tapping screw (10 mm in length,
Synthes, Oberdorf, Switzerland). The screw was used
to determine the insertion point and the direction of
the needle after sacrifice.
Closure of subcutaneous tissue was routinely done using
resorbable suture material (Vicryl® 2–0, Johnson & Johnson
Int., Brussles, Belgium) in a continuous fashion, while the
skin was closed with a skin stapler (Appose ULV, United
States Surgical). No further external stabilization was used.
After repositioning, the augmentation procedure of
the contralateral limb was performed in identical man-
ner. Immediately after surgery lateral and craniocaudal
fluoroscopy images were taken to document the
distribution of the injected material in two projection
planes.
Postoperative treatment
After surgery and recovering from anesthesia, the ani-
mals were kept in small groups and their health status
was checked twice daily. Food and water were offered ad
libitum. Antibiosis and analgesia administrations were
continued via the jugular catheter for 4 days using the
same dosages as perioperatively applied. In addition,
buprenorphine injections i.m. were continued every
4 hours for two applications to reduce postoperative
pain.
After 21 days the staples were removed and the
animals were released to pasture.
Fluorescence labelling
For a dynamic representation of new bone formation
and remodeling, different fluorescence markers were
subcutaneously injected at different time points. Calcein
green (1 ml/kg s.c.; Fluka AG, Buchs, Switzerland) was
applied after 4 weeks, xylenolorange (1 ml/kg s.c.; Fluka
AG) three days before sacrifice.
Evaluation
Computer Tomography Angiography
Computer Tomography Angiography (CTA) of the
thorax was performed in 19 sheep either after cardiovas-
cular complications developed during surgery indicating
pulmonary embolism or in selected cases to visualize the
potential occurrence of pulmonary embolism caused by
bone marrow/fat particles or material deposition. The
CT study was performed with a multi-row unit using 40
rows, slice collimation of 0.6 cm and a pitch of 1. The
contrast medium dose was 700 mg/kg of an iodinated
high-osmolar contrast medium (Telebrix®, 350 mgI/ml,
Guebert, Zurich, Switzerland). The volume of embolized
material was calculated using an automated region of
interest propagation technique with an upper attenu-
ation threshold of 5000 Hounsfield units (HU) and lower
threshold of 300 HU.
Specimen preparation for evaluative procedures
After sacrifice, the tibia and femur were extracted for
final analysis. Augmentation sites were examined macro-
scopically and digital pictures were recorded (Nikon
Digital Camera D5000, © 2009 Nikon Corporation). Sub-
sequently the bones were radiographed using a Faxitron
(Faxitron X-Ray Systems; Hewlett Packard, Mc Minnville
Division, OR) to visualize the detailed bone structure
and detect remaining augmentation material.
To provide a standardized evaluation process, an ap-
propriate harvesting method was designed to locate the
area of interest for histological evaluation.
a b
Figure 3 Injection procedure. Injections were performed with an Optimed CementoRE gun (a) and made in multiple steps under fluoroscopic
control (b).
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By fitting a custom-made axially lined up metal pin
pointer into the head of the screw, the original direction
of the injection needle could be established (Figure 4a).
The bone was fixed to the drill press table with a
custom-made universal joint holder. By manipulating
the holder, the appropriate position could be found by
ultimately aligning the original direction of the injection
needle with the central axis (Figure 4b) of the drill press.
After screw and pin pointer removal, the 32 mm diam-
eter, water-cooled diamond core drill was mounted on
the drill press and an accurate bone cylinder was cored
with the original needle path matching the axis of the
cylinder (Figure 4c). A mark was made with a band saw
on the cortical bone from the entry point of the needle
in distal direction. This allowed consistent positioning of
the sample for μCT scanning and served as a reference
for the cutting of the histology slices.
All bone samples were fixed in 40% ethanol for 1 week,
followed by a series of ethanol dehydration (50-100%)
within 6 days. Once the specimens were fixed in 70%
ethanol, μ-CT analysis was performed by b-cube AG
(Bio-Technopark, Schlieren-Zurich, Switzerland).
After μ-CT analysis and complete dehydration all sam-
ples were degreased in xylene and subsequently infil-
trated in liquid polymethylmethacrylate (PMMA).
Polymerization was carried out in plastic molds closed
with a lid and kept at 4°C for 1 week, thereafter in a
water bath at room temperature until polymerization
occurred. Finally the plastic molds were placed in an
incubator (37°C) uncovered to complete hardening of
the samples.
Ground sections (300 μm) and native fluorescence sec-
tions (350 μm) were cut using a special band saw
(EXAKT® Band System 300/301, EXAKT® Apparatebau
GmbH &Co KG, Norderstedt, Germany). The blocks
were cut lengthwise the needle path. The needle path,
the tip of the needle, and surrounding tissue defined the
region of interest. Before mounting (Cementit® CA 12,
Merz + Benteli AG, Niederwangen, Switzerland) the
sections on plastic slides (ACROPAL, Maagtechnic,
Duebendorf. Switzerland), microradiographs were taken
in the Faxitron (27 kV, 11 s; Fuji Photo Film Co Ltd,
Tokyo, Japan). Ground sections were polished (Exakt®
Mikro- Schleifsystem 400CS, Exakt Apparatebau GmbH,
a b 
c 
Figure 4 Harvesting method. To provide a standardized evaluation process and locate the area of interest, an appropriate harvesting method
was designed: Using a custom-made screw the original direction of the needle could be established (a). A custom-made holder allowed fixation
of the bone to a drill press table aligning the original needle path with the axis of a diamond-coated water-cooled core drill (b). The black arrow
marks the pin pointer used for defining the drill axis. After screw and pin pointer removal, the core drill was mounted on the drill press and a
32 mm diameter bone cylinder was cut (c). The black line in Figure c marks the cutting mark for histology sections with original needle insertion
point and needle path in the center.
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Norderstedt, Germany) and surface stained with tolui-
dine blue. The native sections for fluorescence were
mounted on pellucid, acrylic plexiglas slides (Maagtechnic,
Duebendorf, Switzerland) and wrapped in aluminium foil
to protect slides from bleaching.
For the thin sections the area of interest of the
remaining bone blocks, comprising the tip of the needle
and surrounding tissue, was cut into a smaller segment
and polymerized in special customized Teflon forms
(D. Nadler, JOSSI AG, Islikon, Switzerland) at room
temperature. For hardening, the teflon forms were put
in the incubator at 37°C. Thereafter, blocks were
mounted on plastic frames and cut using a microtome
(Leica® RM 2155, Leica Instruments GmbH, Nussloch,
Germany). After placing the sections on glass slides, they
were deplastified with Methoxyethyl-acetate (Merck AG,
Switzerland) and stained with either toluidine blue or
von Kossa/McNeil.
Histological evaluation
The standardized cutting procedure of all samples along
the original needle path ensured comparability of the re-
sults obtained for the different treatment groups. The
area around the tip of the original needle, where most of
the augmentation material was injected, was identified
as region of interest for analysis.
Ground sections were evaluated histomorphometrically
(Leica Qwin®, Leica Quips®, Leica, Glattbrugg, Switzerland)
to quantify the percentages of new bone, old bone,
granulation tissue, and residual augmentation material
within the area of interest.
First, the ground sections were captured with the
macroscope (Leica Z6 APOA, Leica DFC 420C, Glattbrugg,
Switzerland) as digital images in TIF-format using a 5.6-
fold magnification. To standardize the evaluated area four
circles of 6 mm in diameter were chosen around the tip of
the needle (Figure 5). If the circles contained cortical bone
it was excluded from the region of interest, since more old
bone with high density is present in the cortex. The rest of
the circle was considered as 100%. Circles including the
growth plate were excluded from the analysis, since a
higher rate of new bone was present independently of the
applied material.
Thin sections were semi-quantitative evaluated using
a microscope (Leica® DMR, Glattbrugg, Switzerland) in
a ten-fold magnification. Scores were given for pres-
ence of macrophages, mononuclear cells, osteoclasts,
multinucleated foreign body cells, debris of bone, isles
of not calcified osteoid, agglomeration of mononuclear
cells, percentage of osteoid seam, osteoid thickness,
and material in bulk. Three power fields per section
were assessed with two peripheral and one central in
the injected area. For macrophages, mononuclear cells,
and fibroblasts scores were given in percentages of
cells per power field (0 = 0%; 1 = 1-25%; 2 = 26-50%; 3
>50%). For multinucleated foreign body cells and oste-
oclasts absolute numbers were counted per power field
(0 = 0; 1 = 1-5; 2 = 6-10; 3= >10 cells).
Figure 5 Histomorphometrical evaluation. Histomorphometry was used to quantify the percentage of new bone, old bone, granulation tissue,
and residual augmentation material within the area of interest. For standardization of the evaluated area four circles of 6 mm in diameter were
chosen around the tip of the needle. Cortical bone area was excluded from the analysis (black area in circle 1). The rest of the circle was
considered as 100%. Circles including growth plate were completely excluded from the analysis (circle 3 + 4).
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Fluorescent sections were evaluated at 1.25× magnifica-
tion with a special fluorescence microscope equipped
with different filters appropriate for the used dyes (Leica®
DM 6000B, Leica Microsystems CMS GmbH). To
achieve one adequate picture including the whole area
of interest centered at the tip of the needle, 30 images had
to be taken and merged together to one using a compatible
camera (Leica®DFC 350 FX, Leica Microsystems CMS
GmbH, Mannheim, Germany) and a specific merging
software (Leica® Microsystems CMS GmbH, Mannheim,
Germany).
Focus was placed on differences of dye integration be-
tween groups as well as at different time points (calcein
green at 6 and xylenol orange at 12 weeks).
A semiquantitative evaluation of the recorded images
was performed scoring the percentage of each fluores-
cent dye in the area of interest (considered as 100%) (0
= 0%; 1 = 1-25%, 2 = 26-50%, 3= >50%).
Micro CT evaluation
All samples were measured with a micro-computed tomog-
raphy system (μCT 40, Scanco Medical AG, Brüttisellen,
Switzerland). Semiautomatic masks of sphere shells in dif-
ferent sizes were performed centered at the original pos-
ition of the tip of the needle to evaluate bone volume
density and trabecular thickness of these spheres as well as
the residual radiopaque material. To measure only the tra-
becular bone area, the needle path and the cortical bone
were excluded from the analysis.
Results
Animal model
A total of 63 sheep were treated with the tibia and femur
augmentation model. Sixty-two sheep completed the
12 weeks follow-up period successfully. One animal had
to be euthanized 6 weeks after surgery due to the pres-
ence of a malignant lymphoma in the wall of the urinary
bladder, unrelated to the study treatment.
Augmentation could be achieved successfully in all 63
animals and after a learning curve initially 245/252 aug-
mentation sites were highly reproducible and without
complication. In 7/252 needle positioning problems oc-
curred (see below). The overall surgical procedure for
each hind limb was between 30–40 minutes. In addition,
the minimally invasive surgical procedure led to immedi-
ate recovery and minimal physical stress. After a short
recovery period due to anesthesia (e.g. 30 minutes), the
sheep rose and moved around without lameness. During
the 12 weeks follow up, no signs of inflammation,
wound infections, lameness or other discomfort were
noticed in any of the 62 remaining sheep. Furthermore,
the sheep exhibited no pain response following palpation
of the injected sites.
The surgical technique using the aiming device and
fluoroscopic imaging were particularly useful to inject
the material into a standardized anatomical location.
Under fluoroscopic guidance during surgery, it could
also be verified that consistent amounts of biomaterials
were injected into the trabecular bone and distributed in
a sphere-like shape around the tip of the needle. This
distribution and needle placement could also be verified
using the evaluative procedures. μCT images, microra-
diographs, indicated very consistent and standardized in-
jection areas (see below).
Due to the high density of the trabecular bone at the
injection site, the needle could not be introduced with
manual pressure as it is described in human medicine.
Instead, a hole was drilled and the needle pushed into
the trabecular bone by using a mallet. As mentioned
above, needle-positioning problems occurred in only 7/
252 injection sites. In two of these cases, the needle dir-
ection was slightly different than the original drilling
path resulting in a second hole at the tip of the needle,
although without associated complications. In the
remaining five of these seven cases, the needle position-
ing was assumed to be in the correct place based on
fluoroscopy. However, upon injection a small amount of
the biomaterial was identified within the joint space in
two cases and within the periarticular soft tissues in
three cases. When leakage of material was discovered,
the reposition of the needle was attempted in order to
inject in the predefined area. In three cases there was no
additional leakage during the following injection. In two
cases the injection was cancelled due to persistent leak-
age during the additional attempts.
To inject the augmentation material along the small
diameter of the vertebroplasty needle into the dense
intertrabecular bony space, high injection pressure was
necessary. During the injection procedure the viscosity
of the augmentation materials increased depending on
the duration of the procedure. For the second and third
injection of each augmentation site, a mallet was re-
quired to cautiously push the stylet and force the mater-
ial along the needle into the bone.
The radiopaque materials were visualized without
problems during injection in 208 augmentation sites. In
24 injection sites of 6 sheep of the same group, the ma-
terial could not be identified with fluoroscopy due to in-
adequate radio-opacity of the augmentation material.
This augmentation material was considered not suitable
for injections under fluoroscopic control. In the 20 sham
control sites (5 sheep) no material was actually injected
and thus, could not be visualized. Leakage of augmenta-
tion material was observed in 90 out of 208 injections
(43.3%). No differences between the various materials
could be allocated. Out of those 90 cases, leakage into
the venous circulation occurred in 54 injections (26%),
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whereas leakage into the medullary cavity was observed
in 31 injections (14.9%). Leakage into the periarticular
soft tissues was detected in 5 additional cases (2.4%). A
higher number of leaks during the injection procedure
occurred in the tibia (60%) than in the femur (40%), es-
pecially for the second and third injections at the injec-
tion sites where higher pressure had to be applied for
injection. Despite the high number of biomaterial leaks
observed with fluoroscopy, no clinical symptoms indica-
tive of cardiovascular and/or pulmonary distress were
recorded in 59 sheep (93,7%). In four animals, cardiovas-
cular complications occurred during surgeries including
sudden decrease in arterial blood pressure and end-
expired CO2 by approximately 50%. In those four
animals, CT angiography of the thorax revealed
embolization with augmentation material and bone
marrow, and fat particles. All four animals recovered
without additional complications and completed the 12-
week follow up successfully. Based on this experience, a
randomized and prophylactic CT analysis of subsequent
15 sheep was performed, which demonstrated lung
embolization in 13/15 animals undergoing augmentation
with injection of biomaterial. In the other two animals (2/
15), which belonged to the control group, no embolization
was found. Out of the 17 sheep treated with augmentation
material and demonstrating embolization, 7 sheep (41.2%)
showed embolism caused by bone marrow and fat particles
as well as material deposition, while 10/17 sheep (58.8%) re-
vealed embolism due to material only. Overall 202 emboli
were found in 17 sheep treated with augmentation material.
They occurred in the majority of the cases in the
subsegmental artery within the lung vasculature, for bone
marrow respectively fat particles (12 emboli) and material
(156 emboli), but there were emboli in the segmental (6 fat
emboli/24 material emboli) as well as in lobar artery (1 fat
emboli/3 material emboli), although in lower incidence
with the latter.
Another surgical complication was the breaking of the
needle during the extraction procedure from the bone.
The needle broke, or rather dismantled at the glued
junction between needle and handle. In 4 of 14 cases,
the broken part of the needle could not be removed and
remained in the bone so that the insertion of the self-
tapping screw was not possible. However, no further
complications resulted from this event, although the ab-
sence of the screw made the coring procedure after sac-
rifice less precise, and all bone cylinders contained the
entire area of interest.
Evaluation
The harvesting process of the tibia and femur at sacrifice
were uneventful. μCT, microradiography, and histology
were excellent tools to verify needle placement and ma-
terial distribution within the local anatomic sites. On the
one hand, material deposition was still visible and on the
other hand bone remodeling alongside the original drill
hole and the tip of the needle clearly identified the
location.
Due to early termination of one sheep, only 248
samples were further processed for evaluation. The
harvesting process itself, in terms of drilling the 32 mm
bone cylinder and preparing the area of interest for
evaluation, proved to be reproducible and guaranteed a
highly standardized analysis in 243/248 samples. Three
out of 248 samples had to be excluded from the histo-
logical evaluation since the tip of the needle was not
centered in the cylinder so that the ground sections were
cut in the wrong layer. In the other two, no injection
was performed due to needle positioning problems. All
other samples could be embedded, cut and prepared for
analysis without further complications.
Needle placement could be visualized in the μCT im-
ages due to the fact that the original needle path was not
yet healed. μCT confirmed the suitability of the surgical
method with respect to the consistent placement of the
needle in the desired trabecular bony space. Due to the
presence of an open physis in the proximal tibia in some
animals, the injection resulted in deposition of biomim-
etic material in the trabecular bone within the physis, in
the epiphysis or in the metaphysis (Figure 6). In con-
trast, injections in the femur resulted in consistent de-
position of augmentation material within the distal
femoral epiphysis. The μCT evaluation of the control
animals showed a relatively high bone volume density
(Bone volume/total volume) with thick trabeculae for
both, the femora and the tibiae with a 10% higher bone
volume density for the tibia metaphysis (approx. 35%)
than for the femora (approx. 25%).
With the microradiograph images of the ground sec-
tions, the stage of calcification of the bone samples
within the area of interest and adjacent to remaining
biomaterial could be identified as too could the original
and standardized needle positioning (Figure 7). While
the ground sections were well suited for the assess-
ment of new bone formation, material resorption, and
histomorphometrical measurements (Figure 8a), thin
sections enabled distinctions to be made between
cellular reactions such as osteoblast activation, inflam-
matory responses or degradation and elimination of
biomaterials through macrophages (Figure 8b, c).
The fluorescence sections represented the area of bone
activity at six weeks post surgery (Figure 9a, green col-
ours) and at twelve weeks post surgery (Figure 9b, red
colors) and demonstrated the sphere-like shape distribu-
tion of the biomaterial. A less colored area was observed
in the middle of the injected region, corresponding to
the biomaterial degradation process followed by a red
and a green area towards the periphery. This pattern
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indicated a radial kinetic of new bone formation while
biomaterial was being degraded from the periphery to-
wards the center of the injected region (Figure 9).
Discussion
In our study, a femoral and tibial bone augmentation
model was successfully established and validated using
63 sheep as an alternative to vertebroplasty in the lum-
bar area of sheep. In comparison to the lumbar
vertebroplasty procedures in sheep, the femoral-tibial
augmentation model proved to be safe, easy and quick
to apply, and additionally showed a high level of
standardization including the harvesting of core samples
for histology and the histology evaluation. The surgical
procedure was limited to 30–40 minutes per side, which
was significantly shorter than pilot studies (unpublished
data) with lumbar vertebral augmentation in sheep,
which lasted for several hours. More importantly, the
procedure eliminated severe complications (massive
spinal cord injuries) and reduced animal pain and suffer-
ing. Moreover, the animal model proved to be adequate
to study pulmonary embolism and systemic changes as
sequelae to vertebroplasty as they occur in humans.
The animal model presented served well to evaluate
new biomimetic materials for their osteoinductive,
osteoconductive, and degradation properties as bone
augmentation materials. The advantage was that the
test-materials could be injected with high accuracy and
repeated success within the inter-trabecular spacing of
the intact femoral condyle and proximal tibia. This sur-
gical technique required a specially developed aiming
device and fluoroscopic imaging. Both are also required
for (percutaneous) vertebroplasty in humans. The appli-
cation and visualization of the injected material in the
region of the stifle joint in sheep is much easier com-
pared to the lumbar area, where visualization is impaired
by overlying structures (intestines, rumen, transverse
processes, etc.). The absence of the third plane using
two-dimensional fluoroscopy has to be taken into con-
sideration during needle positioning and injection pro-
cedure to avoid injections out of the predefined area,
which occurred only in 5/252 needle placements. Solid
knowledge of how the trabecular area is distributed
within the proximal tibia and experience of the surgeon
helps to avoid injections into the bone marrow and/or
a 
b 
c 
Figure 6 Micro-CT images. Micro-CT images confirmed the
suitability of the surgical method with respect to the consistent
placement of the needle in the desired trabecular bony space. Due
to the presence of an open physis in the proximal tibia in some
animals, the injection resulted in deposition of biomimetic material
in the trabecular bone within the epiphysis (a), the physis (b), or in
the metaphysis (c).
Figure 7 Microradiograph image. This figure shows a
microradiograph image of a ground section: Stage of bone
calcification in the area of interest and adjacent to remaining
biomaterial could be shown.
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penetration of the caudo-lateral cortex of the tibia with
the needle.
When comparing the results of Hildebrand et al. [23]
retrieved from human bone samples with those of Rubin
et al. [24] from sheep bone, it becomes evident that tra-
becular bone density is much higher in sheep than in
human bone. This comparison of previous findings of
other research teams is in alignment with the results of
our study presented here. Hildebrand et al. measured
for samples of lumbar human spine (2. and 4. vertebra) a
low bone volume density (8-9%) with small trabeculae,
whereas in the current augmentation sheep study bone
volume densities between 25-35% for tibiae and femura
and even higher values in the study of Rubin et al. for
medial femoral condyles (49.1 ± 7.1%). This high bone
density and thick bone trabecula make the needle place-
ment and the injection procedure more challenging in
sheep (personal surgical experience). To place the needle
for percutaneous VP in the osteoporotic, brittle human
bone, it only has to be tapped with a mallet to engage
the cortical bone and afterwards can be pushed forward
a 
b 
c 
Figure 8 Histology samples. Ground sections (approx. 300 μm,
surface stained with toluidine blue) were well suited for assessment
of new bone formation, material resorption and
histomorphometrical evaluation (Figure a), while thin sections
allowed assessment of cellular reactions e.g. osteoblast activation
(Figure b, c, thin black arrows) and biomaterial degradation through
macrophages (Figure b, c, thick white arrows).
a 
b 
c 
Figure 9 Fluorescence section. These fluorescence images show
the bone activity grade at two different time points according to
the integrated fluorescent respectively. Figure a shows the activity
grade at 6 weeks post op (Calcein green), Figure b at 12 weeks post
op (Xylenol orange), and in Figure c both time points are merged
together to one image.
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with manual pressure into the right position [25]. In
contrast, in sheep, a hole had to be drilled first to be able
to push the needle forward into the trabecular bone with
the aid of a mallet. This procedure weakened the needle
and caused breakage at the glued junction between nee-
dle and it’s handle during the extraction procedure of
the needle in 14 cases. Due to the fact that the needle
could not be extracted in only four cases, and no further
complication resulted from this event, the needle type
was not changed during this study. For future studies,
the use of another type of needle, e.g. with a melted
junction (not commercially available at the moment)
could be taken into consideration to avoid needle
breakage.
During the injection procedure, the viscosity of the
augmentation materials increased depending on the dur-
ation of the procedure. As such, forced injections under
high pressure using a mallet were often necessary for the
second and third injections of each injection site along
the small diameter of the vertebroplasty needle into the
dense intertrabecular bony space of the tibial and fem-
oral bone. This could have led to a higher risk for mater-
ial extravasation as well as bone marrow and fat
particles being forced out into the systemic circulation.
The higher percentage of material leakage detected in
the tibia as compared to femur, could be explained by
the approximately 10% higher trabecular bone density
and thicker trabeculae in the proximal tibia metaphysis
than in the femoral condyle, which may have produced
higher resistance to the augmentation material. Pulsed
jet-lavage of bone marrow and fat was reported to
improve injection and lessen the risk of emboli [26].
However, in our hands it did not facilitate injection in
a preliminary study and therefore, the fragmented
injection technique was invented and applied through-
out the study. Although it may not completely mimic
vertebroplasty in osteoporotic human bone, it may be
considered close enough to test substances in sheep for
later use in human bone. During vertebroblasty in
humans, leakage of bone cement is also reported as the
most common complication [25,27]. Therefore, this ani-
mal model could provide important information about
the material properties if leakage occurs during the in-
jection procedure. Due to the absence of chest radio-
graphs or CTs after vertebroplasty on asymptomatic
human patients, cement leakage and pulmonary emboli
occurrence secondary to vertebroplasty may often be
underestimated [16]. In the presented study in sheep,
CT angiography of 19/63 sheep revealed a high number
of asymptomatic pulmonary emboli (13/19 sheep =
68.4%) confirming the opinion of Hulme et al. that CT
is the best method to detect cement leakage and should
be used to report all leaks, including those without
clinical signs [16,28,29].
Another consequence of the forced injections of aug-
mentation material was microdamage and microfracture
of trabecular bone, which occurred centrally to the
injected area, and could be seen in the histology sections
as well as in the fluorescence sections. This trabecular
damage may be less in human osteoporotic bone due to
reduced bone quality and quantitiy (wider trabecular
spaces). Alternatively the diminished bone quality may
also facilitate microfractures within the trabecular struc-
ture, thus resulting in a similar situation as encountered
in sheep. Since osteoporotic bone is weaker, but not im-
paired in proliferation [30], remodeling activities may be
similar to those present within our sheep model. As a
consequence, a resorption zone around the injected area
developed in some cases unrelated to the injected mater-
ial itself.
Conclusions
This tibia and femur augmentation sheep model proved
to be a suitable animal model for screening studies of
new biomaterials intended for bone augmentation of tra-
becular bone and enabled analysis of their biodegradable,
biocompatible and osteoconductive properties. It also
proved to be adequate for the study of the sequelae of
material leakage into the circulation, e.g. pulmonary em-
bolism and following cardiovascular changes.
Overall, we consider it a safe model for the experi-
enced surgeon, resulting in reduced animal suffering and
could serve as an excellent basis for testing bone indu-
cing or enhancing materials for vertebroplasty.
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3 Feasibility Study of a Standardized Novel Animal Model for 
Cervical Vertebral Augmentation in Sheep Using a PTH Derivate 
Bioactive Material  
3.1 Aim of the study 
  (1)  Investigation  of  the  scaled  effects  of  a  PTH  derivate  bioactive  material  for  new  bone  
formation   in   sheep.   Different   concentrations   of   TGplPTH1–34   were   used   as   bio-­‐‑
enhancers,   incorporated   in   a   best   performing   fibrin   matrix   formulation   tested   in  
previous  studies.  
(2)  Development  of  a  novel,  highly  standardized  model  for  vertebral  augmentation  in  
sheep.  Cervical  vertebrae  were  chosen  for  reasons  of   the  best  possible  reproducibility  
and   standardization  of   the  model  with   respect   to   the   surgical   techniques  and  overall  
evaluation  methods  implied.    
3.2 Main conclusions 
Our  cervical  augmentation  model  in  sheep  has  proven  to  be  a  suitable  animal  model  to  
evaluate   biocompatibility   and   bone   formation   of   new   biomaterials   developed   for  
vertebral   bone   augmentation.   Although   the  model   revealed   to   be  more   challenging,  
mainly   due   to   the   onset   of   cardiovascular   complications,   not   previously   seen   in   the  
femoral   and   tibia   augmentation   model,   the   observation   reflected   well   the   human  
situation.    
Nevertheless,  bone  formation  results  demonstrated  that  the  TGplPTH1-­‐‑34  was  safe  to  
use   in   sheep,   since   no   signs   of   inflammation   were   detected   and   fast   biomaterial  
degradation   took   place.   All   treatment   groups   were   more   effective   than   the   sham  
control.  Among  these,  the  medium  concentration  of  TGplPTH1-­‐‑34  induced  the  best  bone  
enhancing   effect.   Whether   this   effect   would   also   be   elicited   in   osteoporotic   bone   in  
humans  is  speculative  at  this  point.  Because  no  suitable  true  osteoporotic,  large  animal  
model  exists  this  could  only  be  verified  in  a  human  clinical  trial.  
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Abstract: Prophylactic local treatment involving percutaneous vertebral augmentation 
using bioactive materials is a new treatment strategy in spine surgery in humans for vertebral 
bodies at risk. Standardized animal models for this procedure are almost non-existent. The 
purpose of this study was to: (i) prove the efficacy of PTH derivate bioactive materials for 
new bone formation; and (ii) create a new, highly standardized cervical vertebral augmentation 
model in sheep. Three different concentrations of a modified form of parathyroid hormone 
(PTH) covalently bound to a fibrin matrix containing strontium carbonate were used. The 
same matrix without PTH and shams were used as controls. The bioactive materials were 
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locally injected. Using a ventral surgical approach, a pre-set amount of material was injected 
under fluoroscopic guidance into the intertrabecular space of three vertebral bodies. Intravital 
fluorescent dyes were used to demonstrate new bone formation. After an observation 
period of four months, the animals were sacrificed, and vertebral bodies were processed for 
µCT, histomorphometry, histology and sequential fluorescence evaluation. Enhanced 
localized bone activity and new bone formation in the injected area could be determined 
for all experimental groups in comparison to the matrix alone and sham with the highest 
values detected for the group with a medium concentration of PTH. 
Keywords: vertebral augmentation; cervical spine; animal model; fibrin matrix; PTH 
derivate; sheep 
 
1. Introduction
Symptomatic compression fractures of vertebral bodies occurring secondary to osteoporosis or 
neoplasia are a major public health problem in our aging society [1–5]. These fractures may cause 
persistent, often excruciating pain, spinal instability and kyphotic deformity, all of which potentially 
impair mobility and reduce the patient’s quality of life [5–7]. Nowadays, percutaneous vertebroplasty 
(VP) is the treatment of choice to mechanically augment the spine. It is a successful, minimally 
invasive surgical procedure [8–10], which seems to be significantly better than non-surgical treatment 
in terms of pain relief, reduced hospital stay and recovery period [11]. The VP technique is performed 
through needle-injection of polymethylmethacrylate (PMMA) bone cement into a collapsed or weakened 
vertebra, this to stabilize, decompress or avoid further compression fractures (prophylactic VP). Common 
complications during the surgical procedure are bleeding at the puncture site, local infection and 
cement leakage into the spinal canal, the paravertebral tissues or the perivertebral venous system [12]. 
Cement extravasation, as well as bone marrow or fat cells forced out of the vertebra into the systemic 
circulation may lead to pulmonary embolism (PE), either without clinical signs or with severe cardiac 
distress symptoms, including death [5]. 
It is well known that PMMA increases the strength and stiffness of the injected vertebral bodies, but 
in the absence of osteoinductive properties and the inability to be degraded and replaced by new bone, 
it will remain just a placeholder. It may also lead to long-term complications, such as damage to 
neurons, toxicity or fracture of adjacent vertebral bodies [3,13]. Therefore, the search for new, preferably 
resorbable biomaterials, containing locally-released bioactive agents with osteoinductive properties to 
strengthen and regenerate weakened vertebral bodies is ongoing. Especially adjacent to the index level 
that was augmented with PMMA for immediate stability, enhancing local bone formation may in the 
future avoid in systemically-ill osteoporotic patients a domino effect of adjacent vertebral compression 
fractures [14].  
A truncated form of the human parathyroid hormone (PTH1-34) is already used as a registered 
pharmaceutical product for osteoporosis treatment. Intermittent systemic injections of PTH1-34 have 
shown anabolic effects on cancellous bone, resulting in increased bone mineral density [15]. PTH is 
able to bind directly to a cell surface receptor on osteoblasts, regulating the production of various 
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cytokines (insulin-like growth factor 1, transforming growth factor !1, interleukin 1 (IL-1) and IL-6) 
and, thus, represents a strong anabolic agent for osteoblast precursors and an indirect anabolic factor 
for osteoclasts (IL-1 and IL-6) [15–17]. It regulates the balance between osteoblasts and osteoclasts, as 
well, thereby exerting a direct effect on bone turnover [15], and plays a primary role in calcium 
homeostasis [18]. In contrast to systemic use, a novel recent strategy is to use an engineered peptide 
variant of the active fragment of parathyroid hormone (PTH1–34) that is enzymatically incorporated 
within a fibrin matrix via the coagulation transglutaminase (TG) factor XIIIa to translate the 
systemically used molecule into a local bone-inducing therapeutic agent [19]. The incorporation of a 
plasmin substrate sequence linker (pl) enables the cleavage of the peptide by endogenous plasmin. Via 
cell migration and infiltration, the peptide is activated and released only into the surrounding tissue for 
the local increase of bone formation. In previous in vivo studies using a tibia and femur augmentation 
model in sheep, various concentrations of this engineered parathyroid hormone (TGplPTH1–34), 
incorporated in different formulations of fibrin matrices, has already shown good results [20]. However, 
it was unknown whether these results could actually be reproduced in the vertebral bodies, this due to 
its different anatomical structure, including high vascularity and sinus formations.  
Safety aspects concerning the augmentation procedure must be considered, such that good visibility 
of the material during injection is key to avoid leakage into the spinal canal and damage to the spinal 
cord. Furthermore, the rheological properties of the material during injection are critical to avoid leakage 
into the vascular system, possibly causing pulmonary embolism or death. The radiopaque inorganic 
salt powder strontium carbonate has proven to be a good contrast agent. Strontium is also known to 
have positive effects on bone formation and for its capability to decrease bone resorption [21,22]. 
Different studies have shown that strontium could induce the replication of osteoblasts [23] and, 
concurrently, the apoptosis of osteoclasts [24] using a pathway involving the extracellular calcium-sensing 
receptor (CaR). An in vivo study of Yang et al. using a calvarial defect model in rats showed that 
locally-delivered strontium was able to act as a bone anabolic agent and could activate the Wnt/!-catenin 
signaling pathway, resulting in an accumulation of extracellular matrix, as well as enhanced osteogenesis 
and bone remodeling [25].  
Good animal models for vertebral augmentation are rare. The sheep has been used as an experimental 
animal model for augmentation in the lumbar spine, although mainly for studying acute cardiovascular 
changes and embolization with immediate sacrifice on the table after augmentation [26–30]. Due to the 
different morphology of ovine vertebral bodies with a more trapezoid and slim vertebral body format 
compared to a round, solid and almost rectangular human vertebral body, a transpedicular approach for 
vertebral augmentation is highly hazardous and difficult to standardize in the lumbar area in sheep. 
Therefore, a new, highly standardized augmentation model in the cervical spine of sheep was developed 
for these experiments, where a ventral approach and customized instrumentation guaranteed the high 
reproducibility of the augmentation procedure. Apart from the safe deposition of the augmentation 
material, this model also involved a risk of pulmonary embolism similar to that found with human vertebral 
augmentation. Therefore, the study results may be better transferable to the human vertebral bone structure. 
The aim of this study was to: (i) investigate the scaled effects of PTH derivate bioactive material as 
an enhancer for new bone formation in sheep; and (ii) create a novel, highly standardized animal 
model for vertebral augmentation in sheep. To reach aim (i), different concentrations of TGplPTH1–34, 
incorporated in the best performing fibrin matrix formulation from previous studies, were used as 
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bioenhancers. For aim (2), cervical vertebrae in sheep were targeted focusing on the reproducibility 
and standardization of the model, including the surgical technique and overall evaluation. To the 
knowledge of the authors, this is the first report for both using the local application of an engineered 
peptide variant (TGplPTH1–34) as a bioactive agent and reporting a standardized animal model in the 
cervical spine of sheep. 
2. Material and Methods 
2.1. Study Design and Experimental Animals 
Seventeen adult female Swiss alpine sheep with a mean age of 3.2 years (range from 2 to 5 years) 
and a mean weight of 72.6 kg (54–89 kg) were used for this study, conducted adhering to the Swiss 
regulations of Animal Welfare (TSchG 455), with a specific permission granted by the federal 
authorities (Application No. 151/2009). 
Using a cervical vertebral augmentation model in sheep, three different concentrations of a 
modified form of parathyroid hormone (TGplPTH1-34) covalently bound to a fibrin matrix containing 
strontium carbonate, the same matrix without any TGplPTH1-34, as well as sham controls were tested 
and compared. Three vertebrae per sheep were augmented. Each group consisted of three sheep, with 
the exception of Group 2, where two sheep died during surgery, and therefore, two additional sheep 
were used (for the group distribution, see Table 1).  
Table 1. Group distribution and clinical signs of pulmonary embolism. PTH, parathyroid 
hormone; PE, pulmonary embolism.  
Group Material 
Number of 
animals 
Number of 
evaluated vertebra
Clinical signs of pulmonary 
embolism 
Matrix alone FS+SrCO3 3 8 2× mild clinical signs 
Low FS+SrCO3+PTH low conc. 5 9 
2× severe clinical signs led to death,
1× mild clinical signs 
Medium FS+SrCO3+PTH low conc. 3 8 1× mild clinical signs 
High FS+SrCO3+PTH low conc. 3 9 1× mild clinical signs 
Sham No materials 3 9  
FS: Fibrin scaffold; SrCO3: Strontium carbonate; PTH low-high: TGplPTH1-34 concentration low-high; 
Mild clinical signs of PE: intermittend bradycardia, Hypercapnia and mild oxygen desaturation 
Using a ventral surgical approach and a customized aiming device, a fixed amount of biomaterial 
per vertebra (1–1.5 mL) was injected under fluoroscopic guidance in a standardized trajectory and to a 
standardized depth into the intertrabecular space of three vertebral bodies per sheep (between C2–C6). 
For the sham controls, the same procedure was performed without material injection. To detect 
pulmonary emboli, non-invasive airway dead space measurements were performed during surgery, as 
well as CT angiography of the thorax in all sheep prior to and after surgery [31]. After 16 weeks of 
follow-up, the sheep were sacrificed, and the harvested vertebral bodies were further processed for 
macroscopic assessment (signs of inflammation and irritation), µCT analysis and histology, including 
histomorphometry and evaluation of fluorescent dye incorporation. 
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2.2. Test Material 
Three different concentrations (low, medium, high) of a modified inactivated form of PTH1-34 
(TGplPTH1-34) with a transglutaminase hook (TG-Hook) were evaluated (pending patent application) [19]. 
Using the TG-hook, the peptide was covalently bound and immobilized onto a fibrin matrix during the 
coagulation process and later locally released in vivo and activated by plasmin-induced proteolytic 
cleavage (via a plasmin substrate sequence linker (pl)) after cellular infiltration and replacement of the 
fibrin matrix with a newly secreted extra-cellular matrix. As a contrast agent for better radio-opacity 
and to improve the rheological properties during the injection procedure, 40% weight volume (w/v) 
strontium carbonate was added to the formulation. In one of the test groups, only the fibrin matrix 
including the strontium carbonate was used without PTH1-34. 
2.3. Instruments/Equipment 
In addition to the routine surgical instruments, a customized aiming device was developed to 
guarantee the reproducibility of surgical access and to standardize the access point on the bone surface 
for injection into the trabecular bone of the vertebral body (Figure 1a–c). Using a ventral surgical 
approach, the aiming device allows an exact drilling and subsequent positioning of the injection 
needle. This can be achieved via a central drill guide that is positioned on the promontorium of the 
caudal aspect of the vertebral body (Figure 1a), an aiming targeting tip lined up with the vertebra 
midline and two sharp long fixation dents (beside the midline) resting on the cranial deeper part of the 
vertebral body. An oval hole allows monitoring the drill guide tip placed on the promontorium while 
the drill guide remains positioned (Figure 1b).  
Figure 1. This figure shows the aiming device in a correct position using a ventral approach 
to the vertebral body. (a) The lateral view represents the central drill guide in the correct 
position on the promontorium of the caudal aspect of the vertebral body. (b) The craniocaudal 
view shows the drill guide positioned on the promontorium, with an aiming targeting tip 
lined up with the vertebra midline and two sharp long dents, arranged symmetrically lateral 
of the midline, resting on the cranial deeper part of the vertebral body. In (c), the aiming 
device is shown as a whole with the handle, central drill guide and fixation dents. 
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For injection of augmentation material, a 10 G (3.2-mm diameter) 100 mm-long special vertebroplasty 
needle (1394-1010, Optimed Medizinische Instrumente GmbH, Ettlingen, Germany) (Figure 2b) and 
an Optimed CementoRE gun (1392-0000, Optimed Medizinische Instrumente GmbH, Ettlingen, Germany) 
were used (Figure 2c). 
Figure 2. The images (a–e) show the different steps of the surgical procedure: (a) an 
aiming device was used for repeatable and standardized drilling; (b) the vertebroplasty 
needle was correctly positioned; (c) material injection was performed in multiple steps 
using the Optimed CementoRE gun. Fluoroscopic imaging was used for repeatable and 
standardized drilling (d) and to detect material leakage during injection, as seen in (e), 
where leakage into vertebral vessels was detected at the caudal part of the two injected 
vertebrae (see the !). 
 
2.4. Anesthesia  
A standard anesthetic protocol was used. After 24 hours of fasting and 30 minutes before induction 
of anesthesia, the animals were premedicated with buprenorphine (Temgesic®, 0.01 mg/kg i.m., Essex 
Chemie AG, Lucerne, Switzerland) and xylazine (Rompun® 2%, 0.1 mg/kg i.m., Streuli Pharma, 
Uznach, Switzerland). A catheter was placed into the vena cephalica antebrachii of one of the front 
legs and prophylactic antibiotics (Penicillin Natrium® 35,000 IU/kg i.v., G. Streuli Pharma, Uznach, 
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Switzerland; gentamicin, Vetagent®, 4 mg/kg i.v., Veterinaria AG, Zurich, Switzerland), as well as a 
pre-emptive analgesic drug, carprofen (Rimadyl®, 4 mg/kg i.v., Pfizer SA, Zurich, Switzerland), were 
given intravenously. A booster for tetanus (Tetanus Serum Intervet, 3,000 IU/sheep s.c., Veterinaria 
AG Zurich, Switzerland) was administered subcutaneously. 
Anesthesia was induced with diazepam (Valium®, 0.1 mg/kg i.v., Roche Pharma AG, Rheinach, 
Switzerland), ketamine (Narketan 10®, 3 mg/kg i.v., Vetoquinol AG, Belp-Bern, Switzerland) and 
propofol (Propofol®, 0.4–2 mg/kg i.v., Fresenius Kabi, Stans, Switzerland), the latter administered to 
effect. After laryngeal desensitization with lidocaine spray (xylocaine spray 10%, 3 pumps of 0.1 mL 
each, Astra Zeneca AG, Zug, Switzerland), the trachea was intubated and correct placement was 
confirmed by expired carbon dioxide monitoring (FetCO2). Anesthesia was maintained with a balanced 
anesthetic protocol employing the administration of isoflurane (1%–2%) in oxygen via an adult  
F-circuit (circle system, Intersurgical, Berkshire, U.K.), a variable rate infusion of propofol (Propofol®,  
0.5–1 mg/kg/h, Fresenius Kabi, Stans, Switzerland), as well as lidocaine given at the beginning of  
the surgical procedure as bolus (1 mg/kg) and afterwards as constant rate infusion (Lidocaine®,  
40 !g/kg/min, Kantonsapotheke, Zurich, Switzerland).  
Monitoring parameters included electrocardiogram (ECG), heart rate, pulse rate and invasively 
measured blood pressures (systolic, mean and diastolic arterial) via an arterial catheter in an auricular 
artery. Furthermore, inspired and expired concentrations of carbon dioxide, oxygen and isoflurane, as 
well as esophageal temperature and saturation of arterial blood (SpO2) were monitored. All parameters 
were constantly measured and recorded in 10-minute intervals. Intraoperatively, fluids Ringer’s lactate 
solution (Ringer Lactat®, Bichsel, Interlaken, Switzerland) was administered at a rate of 10 mL/kg/h, 
and heat was applied using a forced-air warming device (Bair Hugger® 505, Augustine Healthcare, 
Eden Prairie, MN, USA).  
Intermittent positive pressure ventilation was applied (if needed) to maintain normocapnia. A  
Swan-Ganz-catheter was inserted via the jugular vein into the pulmonary artery to allow invasive 
measurements of pulmonary artery pressure and cardiac output. Physiologic airway dead space 
measurements were performed with the non-invasive cardiac output monitor, NICO® (Respironics 
Novametrix, Inc., Wallingford, CT, USA). The results of this comparison between invasive and  
non-invasive measurements are not included in this paper and will be described elsewhere.  
2.5. Surgical Procedure  
The anesthetized sheep were placed in dorsal recumbency with the forelimbs retracted caudally and 
fixed to the surgery table. The neck was bent slightly upwards for an easier approach to the vertebral 
bodies. The correct position of the sheep was further supported with an inflatable surgery mat, rubber 
foam rolls and wedges. To prevent bloating and regurgitation, a stomach tube was placed prior to 
surgery. The tube was maintained throughout the entire surgery until recovery in sternal recumbency. 
The ventral aspect of the neck was shaved and surgically scrubbed and cleansed. The animals were 
draped according to routine. A midline skin incision was performed from the pharyngeal region 
extending caudally to the level of the thoracic inlet. The subcutis and superficial facial planes were 
bluntly dissected to expose sternohyoid and pharyngeal muscles. A blunt and careful dissection was 
made in the midline in between the left and right sternohyoid muscles. The jugular vein, carotid artery, 
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vagal nerve, trachea and oesophagus were carefully retracted using a blunt retractor wrapped in gauze. 
Exposure of the ventral aspect of the vertebral bodies was maintained by securing the retractors in 
place. The desired vertebra was identified by palpating the transverse processes and the intervertebral 
spaces. The identification of the area of interest was performed using two anatomical landmarks: the 
promontorium caudal to the desired vertebral body and the deeper laying cranial aspect of the vertebra. 
The muscles covering the caudal aspect of the vertebral body were bluntly divided to expose the area 
of interest. Hemostasis was meticulously kept using electrocautery. The aiming device was placed with 
the tip of the drill guide at the promontorium in the cranial drill direction (Figure 1a–c). 
Under fluoroscopic control, the correct placement of the aiming device and subsequent needle 
positioning was validated to avoid inaccurate injections. A drill hole with a diameter of 2.8 mm was 
created in the vertebral body (Figure 2a) followed by placing the special vertebroplasty needle using a 
Kirschner wire as guide for the correct direction of the needle path. Afterwards, the needle was pushed 
forward, till its tip was firmly seated and surrounded by bone (Figure 2b). 
Material injections were done in multiple steps under fluoroscopic guidance (Figure 2e). Needle 
filling with augmentation material was done slowly with the aid of the Optimed CementoRE gun 
(Figure 2c). Subsequently, the gun was removed, and the stylet was used to push the material into the 
bone, so as to provide exact quantities of injectate. The filling-clearing procedure was repeated one or 
two times, until a target between 1.5 and 1.8 mL was injected within the intertrabecular space. Using 
fluoroscopy, the leakage of material into a vessel and thrombus formation was recorded, the injection 
needle slightly advanced and injection continued. At completion of the procedure, the vertebroplasty 
needle was removed and the insertion point closed with a 3.5-mm diameter self-tapping screw (8 mm 
in length, Synthes, Oberdorf, Switzerland) (Figure 2d and 2e). The screw was used to later determine 
the direction of the needle and insertion point at the time of sacrifice.  
Afterwards, the muscles were repositioned, and the closure of the soft tissue was routinely done 
using resorbable suture material (Vicryl® polyglactin, 2-0, Johnson & Johnson Int., Brussels, Belgium) 
in a simple continuous fashion, while the skin was closed with a skin stapler (Appose ULV, United 
States Surgical). The Swan-Ganz catheter was removed, and a normal catheter (Vygonyle S® G14, 
Vygon GmbH, Aachen, Germany) was placed in the other jugular vein. Intra-operative fluoroscopy 
images were taken in right lateral view throughout the surgery to document the surgical technique and 
the injection steps. Immediately after surgery, fluoroscopy images in latero-lateral and ventrodorsal 
view were taken to document the distribution of the injected material in two projection plans. 
2.6. Postoperative Treatment 
The animals were supervised during recovery from anesthesia until they could stand on their own, 
walk around and eat without further complications. They were kept in small groups, and their health 
status was checked twice daily. Antibiotic and analgesia administrations were continued for 4 days 
intravenously using the same dosage as perioperatively applied.  
Additional analgesia treatment was provided to reduce postoperative pain using intramuscular 
injections of buprenorphine (Temgesic®, 0.01 mg/kg, Essex Chemie AG, Luzern, Switzerland) every  
4 hours for a total of three applications.  
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2.7. In Vivo Fluorescence Labeling 
Different fluorescence markers were subcutaneously injected at 6 weeks (calcein green, 5 mg/kg 
BW s.c., Fluka AG, Buchs, Switzerland), 12 weeks (xylenol orange, 90 mg/kg BW s.c., Fluka AG) and 
three days prior to sacrifice (oxytetracycline, 20 mg/kg BW s.c., Engemycin® 10%, MSD Animal 
health GmbH, Lucerne, Switzerland) to dynamically represent new bone formation and remodeling. 
2.8. Sacrifice and Specimen Preparation for Evaluative Procedures 
All animals were sacrificed after a follow up period of 16 weeks, and the three treated cervical 
vertebrae were harvested for final analysis. Augmentation sites were examined macroscopically, and 
digital photographs were taken to document tissue reaction at the surgical site (Nikon Digital Camera 
D5000, 2009 Nikon Corporation©). Radiographs were taken using a Faxitron (Faxitron X-Ray 
Systems, Hewlett Packard, Mc Minnville Division, OR, USA) to visualize the detailed bone structure 
and detect remaining augmentation material. Subsequently, each vertebra was cut in a smaller segment 
containing only the injected vertebral body for evaluative procedures. An additional radiograph was 
performed to qualitatively assess new bone formation in the vertebral bodies. The bone samples were 
fixed in 40% ethanol for one week, followed by a series of ethanol dehydration steps (50%–100%) 
within 6 days. !-CT analysis of the specimen was performed in 70% ethanol fixation (b-cube AG,  
Bio-Technopark, Schlieren-Zurich, Switzerland). After complete dehydration, the samples were 
degreased in xylene and subsequently infiltrated in liquid methymethacrylate (MMA) until polymerization 
occurred [20]. Using a special band saw (EXAKT® Band System 300/301, EXAKT® Apparatebau 
GmbH &Co KG, Norderstedt, Germany), cutting of the ground sections (300 !m) and native 
fluorescence sections (350 !m) were performed. The sections were oriented along the original needle 
path in the midline of the vertebral body, with the needle path itself, the tip of the needle and the 
surrounding tissue defined as the region of interest. Before mounting (Cementit® CA 12, Merz + 
Benteli AG, Niederwangen, Switzerland) the sections on plastic slides (ACROPAL, Maagtechnic, 
Duebendorf, Switzerland), microradiographs were taken with the Faxitron (27 kV, 11 s; Fuji Photo 
Film Co Ltd, Tokyo, Japan). Ground sections were polished (Exakt® Mikro- Schleifsystem 400CS, 
Exakt Apparatebau GmbH, Norderstedt, Germany) and surface stained with toluidine blue. The native 
sections for fluorescence were mounted on pellucid, acrylic Plexiglas slides (Maagtechnic, Duebendorf, 
Switzerland) and wrapped in aluminum foil to protect slides from bleaching. For thin section 
preparation, the remaining bone blocks were cut in smaller segments comprising only the tip of the 
needle and surrounding tissue. Polymerization was achieved in special customized Teflon forms  
(D. Nadler, JOSSI AG, Islikon, Switzerland) [20]. Afterwards, the small blocks were mounted on 
plastic frames and cut using a microtome (Leica® RM 2155, Leica Instruments GmbH). After 
mounting on glass slides and pressing for two days in the incubator, the sections were stained with 
either toluidine blue or van Kossa/McNeal.  
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2.9. Analysis 
2.9.1. Micro-Computed Tomography Analysis 
Micro-computed tomography (!CT) analysis of the vertebral bodies was performed to qualitatively 
assess the bone volume density and trabecular thickness, as well as the location and amount of residual 
augmentation material within the treated levels. The samples were scanned by a micro-computed 
tomography system (!CT 40, Scanco Medical AG, Brüttisellen, Switzerland). The measured data were 
filtered and then segmented to separate the bone and the potentially present residual biomaterial from 
the background using a global thresholding procedure. For samples with identified residual 
biomaterial, a multi-level segmentation technique was used to segment bone and residual material in 
two separate phases, whereas for samples without residual material, a simple segmentation procedure 
was applied to separate bone from background. For all samples, the same thresholds were used. The 
measurements were performed using semiautomatic masks of nine overlapping hollow sphere shells in 
different sizes centered at the tip of the needle, used to calculate average bone volume density and 
trabecular thickness within each sphere shell (Figure 3).  
Figure 3. This figure represents one slice through the nine hollow sphere shells used for 
the analysis. The needle path and the cortical bone areas were excluded from the analysis. 
 
Figure 4. This figure shows the different masks created for density analysis. (A) The inner 
mask to exclude the cortical bone from the analysis. (B) The defined cylinder (Ø 3.5 mm) 
representing the original needle path with two manually determined points “tip” and 
“base”. This cylinder was subtracted from the hollow sphere shells. Furthermore, the part 
of the sphere shell not lying in the trabecular bone was subtracted from the sphere shell. 
(C) An example of the final sphere shell mask.  
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Using these sphere shells, the calculation of average material distribution and bone volume density 
in correlation to the radial distance from the tip of the needle was possible. To measure only the 
trabecular bone area, a region correlating to the cylindrical needle path and the cortical bone shell were 
excluded from the analysis. For the original needle path, a cylinder slightly larger than the original 
diameter of the needle was chosen, in order to exclude the region of any bone debris produced during 
the needle insertion procedure (Figure 4).  
Integrating the values of the spherical shell data, the bone volume density in full thickness spheres 
could be computed (Figure 5).  
Figure 5. This figure shows one slice with 4 full thickness spheres with 8 mm, 12 mm,  
16 mm and 20 mm diameter, respectively. 
 
Figure 6. This figure shows a full sphere of 12 mm in diameter and a sphere shell with 
more than 12 mm in diameter. The inner ‘Sphere12’ is representative of the injected region 
of biomaterial, subsequently called ‘augmented’. The outer ‘Shell12+’ is representative of 
the untreated bone region and used as internal sample reference, subsequently called 
‘unaugmented’. Needle path and cortical bone regions (grey shaded areas) were excluded 
from the analysis. 
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With the injected volume of approximately 1–1.5 mL material, the sum of sphere shells up to  
12 mm in diameter were assumed as the injected area (consecutively called the full thickness sphere), 
whereas the sum of all larger sphere shells were assumed to be non-injected (Figure 6). 
2.9.2. Histological Evaluation 
Histomorphometry was performed using digitally recorded images of the ground sections (5.6-fold 
magnification, macroscope Leica Z6 APOA, Leica DFC 420C, Glattbrugg, Switzerland). For 
standardization of the evaluated area, three circles of 5 mm in diameter were chosen around the tip of 
the needle (Figure 7). The structures of interest within these circles were manually color-highlighted 
interactively using Adobe Photoshop Elements 10 (Adobe Systems, San Jose, CA, USA). Old bone 
was highlighted in blue (R: 0; G: 210; B: 255), newly formed bone in green (R: 34; G: 79; B: 7), 
granulation tissue in pink (R: 242; G: 40; B: 211) and residual augmentation material in beige (R: 198; 
G: 156; B: 96) using a standard pixel-detecting tool of Adobe Photoshop. Afterwards, the colored 
images were analyzed using a special image analysis software (QUIPS/QWIN, Leica standard, V.3.0, 
2003, Leica-Microsystems, Heerbrugg, Switzerland), and the colored fractions were automatically 
detected and measured in pixels using binary segmentation of a standard macro-routine. Afterwards 
the pixels of each whole circle were set as 100% and the different colored fractions converted into 
percentages. Circles including the growth plate were excluded from the analysis, to avoid higher rates 
of new bone present independently of the applied material. Cortical bone in the circles was excluded 
from the region of interest and the rest of the circle considered as 100%, since disproportional  
high-density old bone is present in the cortex. The average of all three circles per sample were used for 
statistical analysis. To reduce any inter-observer variability, only one examiner performed the analysis; 
certain randomly chosen images were evaluated twice as the control.  
Figure 7. Example of a histology ground section for histomorphometric evaluation. Three 
circles (Ø 5mm) at the tip of the needle were chosen for the evaluation of the percentage of 
old bone, newly formed bone, total bone and granulation tissue within the area of interest.  
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Thin sections were evaluated semi-quantitatively for cellular reactions using a microscope (Leica® 
DMR, Glattbrugg, Switzerland) in 10- to 20-fold magnification. Scores were given for presence of 
macrophages, mononuclear cells, osteoclasts, multinucleated foreign body cells, amount of osteoid 
seam, thickness of osteoid seam and amount of residual material (Table 2). Three power fields per 
section were assessed with two peripheral and one central in the injected area. The average of all three 
scoring areas for each augmentation site was statistically evaluated.  
Table 2. Indicators for cellular reactions evaluated in the semi-quantitative histology 
scoring. Low scores indicate low numbers and high scores high numbers of cells, material 
or osteoid seams.  
Indicator 
Observable value 
(in the circular scoring area) 
Scoring range 
(for each single circular 
scoring area) 
Mononuclear cells 
Percentage of mononuclear cells compared to the 
overall number of cells 
0–3 
Macrophages 
Percentage of macrophages compared to the overall 
number of cells 
0–3 
Multinucleated foreign 
body cells 
Absolute number of multinucleated foreign body cells 0–3 
Fibroblasts 
Percentage of fibroblast compared to the overall 
number of cells 
0–3 
Osteoclasts Absolute number of osteoclasts 0–3 
Amount of osteoid seam Percentage of bone surface covered by osteoid 0–3 
Thickness of osteoid seam 
Thickness of the osteoid compared to the average size 
of an osteoblast 
0–3 
Residual material Percentage of surface occupied by residual material 0–3 
 
Fluorescent sections were evaluated semi-quantitatively for the differences of dye integration 
between groups and at different time points (calcein green at 6 weeks, xylenol orange at 12 weeks and 
oxytetracycline at 16 weeks post-surgery). Digital images of the region of interest at the tip of the 
needle were recorded. Therefore, 30 single images were taken in a 1.25 magnification and merged 
together using a special microscope, camera and specific merging software (“Stitching function”; 
Leica® DM 600B, Leica® DFC 350 FX, Leica® Microsystems CMS GmbH, Mannheim, Germany). 
Scores were given for the percentage of each fluorescent dye in the region of interest (considered as 
100%) with 0% = 0, 1%–25% = 1, 26%–50% = 2, >50% = 3. 
2.9.3. Statistical Analysis 
Results were analyzed statistically by means of PASWStatistics® software (Base for Mac OS X, 
Version 21.0, Chicago, IL, USA). Overall differences between groups were assessed using a factorial 
analysis of variance (ANOVA). Differences between individual groups were calculated with post hoc 
tests according to Scheffe. p-values < 0.05 were considered statistically significant. 
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3. Results 
3.1. Surgery, Postoperative Period and Sacrifice  
A total of 17 female adult sheep were treated with the cervical vertebral augmentation model. Out 
of these 17 animals, two (11.8%) died during surgery after augmentation of the first vertebra. Death 
was attributed to severe cardiac distress, including a sudden decrease in arterial blood pressure and 
end-expired CO2 by approximately 50%, followed by cardiac arrest. The other 15 sheep completed the  
16-week follow-up period successfully. Out of these, 5/15 animals (29.4%) developed mild symptoms 
of pulmonary embolism, but recovered while still in surgery without further complications. No 
significant difference between treatment groups for the incidence of pulmonary embolism was found. 
Although only seven animals showed clinical signs of pulmonary embolism, the leakage of biomaterial  
(0.1–0.5 mL) into the venous circulation was observed in 19/36 (52.7%) material-treated augmentation 
sites (i.e., sham group excluded) using fluoroscopy during the injection procedure. 
In total, 43/45 augmentation sites were treated. Using the aiming device and fluoroscopic imaging 
for standardized needle placement and material injection, the needle could be positioned successfully 
during the first attempt in 42/45 augmentation sites (three vertebrae per sheep, 15 remaining sheep). 
Only in 3/45 augmentation sites (medium and high concentration groups and sham group), needle 
positioning was unsuccessful in the first attempt. In these cases, the drill guide was repositioned and 
drilling was repeated due to a misalignment of the first drilling. In one of these injection sites (medium 
conc. group), no material could be injected in the vertebra, because the first drilling had perforated the 
opposite cortical bone with a disproportional high risk of leakage outside the vertebral body into the 
spinal canal. Another unplanned deviation of the surgical procedure occurred in the first sheep of the 
study, where only two vertebrae were treated due to a very long anesthesia and surgery period. For 
health and survival reasons, the surgery was stopped after the augmentation into the second vertebra.  
Another minor surgical complication at one augmentation site was the breaking of the needle during 
the extraction procedure from the bone. The small broken part of the needle remained within the bone. 
However, no further clinical complications resulted from this event, and the augmentation site was 
evaluated according to the standard protocol. 
Under fluoroscopic guidance during surgery, all formulations showed good radio-opacity and a 
sphere-like shape distribution around the tip of the needle with an injected amount between 1 and  
1.5 mL of augmentation material. 
The overall surgical procedure for each animal lasted between 45 and 60 minutes. After a short 
recovery period following anesthesia (approximately 30 minutes), the sheep roamed freely in the 
stables or on pasture without lameness or other visible discomfort. During the 16-week follow-up, no 
signs of wound infections or inflammation were noticed in any of the 15 remaining sheep. 
The en-bloc harvesting process of the cervical spine, including all treated vertebra, was uneventful, 
and all samples could be prepared for further evaluation. By setting the screw for needle direction after 
sacrifice and using the customized aiming device during the surgical procedure, the central area of 
augmentation within the vertebral bodies could be found in all samples with a longitudinal cut through 
the original needle path.  
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3.2. Analysis  
3.2.1. Micro-Computed Tomography  
Results of µCT are given in Table 3. With the µCT images, the suitability of the surgical method 
could be confirmed with respect to a consistent, standardized needle placement in the desired and 
predicted trabecular bone space. For all treatment groups, a higher bone volume density and an increased 
trabecular thickness was found when compared to the sham group, indicating a bone enhancing effect 
of all material formulations (Table 3, Figure 8). Trabecular thickness was similar in the treated groups 
and the matrix alone group. This was combined with a radial distribution for both parameters with 
higher values central in the augmented area (until sphere 12) and decreasing values to the 
unaugmented area (sphere >12). Residual augmentation material was only detected in the matrix-only 
treatment group (no TGplPTH1-34, 4/7 samples) and the low concentration group (2/9 samples). No 
other treatment group had residual material detected. 
Table 3. Means and SD of the morphometric µCT measurements for BV/TV (bone volume 
density) and Tb.Th. (trabecular thickness) for three spheres: 8 mm, 12 mm and 16 mm. 
Note that the BV/TV in the larger 12 mm sphere is higher for the treated groups, while 
trabecular thickness is equal to the matrix alone group and only higher compared to the sham.  
Group 
BV/TV [%] 
(sphere 8 mm) 
BV/TV [%] 
(sphere 12 mm) 
BV/TV [%] 
(sphere 16 mm) 
Tb.Th [mm] 
(sphere 8 mm) 
Tb.Th [mm] 
(sphere 12 mm) 
Tb.Th [mm] 
(sphere 16 mm) 
Matrix alone 52.2 ± 9.0 44.7 ± 11.0 41.0 ± 8.9 0.43 ± 0.07 0.38 ± 0.08 0.34 ± 0.06 
Low 52.9 ± 8.6 47.3 ± 6.0 45.6 ± 5.1 0.34 ± 0.07 0.30 ± 0.06 0.31 ± 0.08 
Medium 61.5 ± 3.8 55.1 ± 4.8 50.3 ± 4.7 0.40 ± 0.10 0.37 ± 0.08 0.34 ± 0.08 
High 50.2 ± 16.6 46.7 ± 15.5 43.8 ± 14.1 0.34 ± 0.11 0.31 ± 0.10 0.28 ± 0.08 
Sham 43.6 ± 10.3 45.0 ± 9.1 46.5 ± 8.6 0.27 ± 0.07 0.27 ± 0.07 0.28 ± 0.06 
Figure 8. Three representative sagittal sections of the !CT scans: (a) a sample of the 
control group; (b) a sample of the group with medium TGplPTH1-34 concentration is 
illustrated; (c) a sample of the group with high TGplPTH1-34 concentration is shown. A 
denser bone area in the injected region could be distinguished for the samples in (b) and 
(c), where the augmentation material was injected. Increased trabecular thickness is visible 
in the circles of the outlined augmentation area. 
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3.2.2. Histomorphometry 
Exact percentages of new bone formation, old remaining bone matrix, granulation tissue and total 
bone are reported in Table 4 and Figure 9. 
Table 4. Histomorphometrical measurements of old bone, new bone, total bone and 
granulation tissue (in percentage of total area measured). 
Group Old bone matrix New bone matrix Total bone matrix Granulation tissue 
Matrix alone 22.4 ± 3.4 19.6 ± 8.6 42.0 ± 8.0 58.0 ± 8.0 
Low 15.3 ± 2.3 26.3 ± 5.5 41.9 ± 5.2 58.4 ± 5.2 
Medium 15.5 ± 3.5 32.0 ± 3.6 47.6 ± 3.6 52.5 ± 3.6 
High 9.6 ± 10.5 27.5 ± 9.7 37.1 ± 12.9 62.9 ± 12.9 
Sham 34.2 ± 6.9 7.1 ± 8.2 41.4 ± 12.4 58.7 ± 12.4 
Figure 9. The bars show the mean and SD values of the histomorphometrical measurements 
of old bone, new bone and granulation tissue (as a percentage of the total area measured). 
All treatment groups showed significantly higher percentages of new bone than the control 
group. In contrast, the sham group had the highest percentage of old bone (significant 
differences compared to the sham group are highlighted with asterisks; the bracket 
illustrates the significant difference between the matrix alone group and the group with 
medium TGplPTH1-34). 
 
As in the µCTs overall, a high percentage of new bone was found in the augmented region  
(19.6%–32%) for all treatment groups, whereas in the sham group, new bone was only detected at the 
border of the needle path (7.1%). In all treatment groups, the area adjacent to the tip of the needle 
seemed to be mainly filled with new bone, partly due to proliferation and partly to an enhanced 
remodeling and bone formation process (Figure 10).  
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Figure 10. Examples of toluidine blue-stained ground sections of all groups; the area at the 
tip of the needle of all treatment groups showed mainly newly formed bone (indicated by 
darker blue areas), whereas for the sham group, new bone only was detectable at the border 
of the needle path. Note the increased trabecular thickness in the augmented area.  
 
 
Overall differences between groups in percentage for old and new bone were significant at  
p = 0.000. When compared individually, all treatment groups showed significantly higher percentages 
of new bone than the sham group (p-value ranging between 0.000 and 0.029). In contrast, the sham 
group had the highest percentage of old bone compared to all treatment groups (p-value ranging 
between 0.000 and 0.009). No significant differences between groups were found for the percentages 
of granulation tissue (52.4%–62.9%) and of total bone (37.1%–47.56%). The bone remodeling process 
was pronounced in all specimens of the treatment groups, but especially for the groups with higher 
concentrations of TGplPTH1-34. The highest average for new bone (32%) was found for the group with 
a medium concentration of TGplPTH1-34. with statistical significant differences also for the group with 
matrix alone (19.6%) (p = 0.042) (Figure 9). 
3.2.3. Fluorescence  
Means and SD from semi-quantitatively scoring fluorescence sections are reported in Table 5. No 
fluorescent dye (tetracycline) was detected at 16 weeks, so that it was left out of the table. 
The fluorescence images of all treatment groups demonstrated the sphere-like shape distribution of 
the biomaterial with a red colored area in the middle and a green area towards the periphery. This 
pattern indicated a radial progression of new bone formation with enhanced bone activity, and 
precipitation of the fluorescence markers starting in the periphery and the biomaterial being progressively 
degraded, starting from the periphery towards the middle of the injected region (Figure 11).  
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Table 5. Means and SD of the semi-quantitative fluorescence scores for all groups and at 
different time points show that increased new bone formation occurred mainly at the early 
time point at six weeks in all PTH derivates compared to controls. At 12 weeks, new bone 
deposition was lower in all groups, except the matrix alone group.  
Group Calcein green (6w.p.OP) Xylenol orange (12w.p.OP) 
Matrix alone 0.8 ± 0.4 0.9 ± 0.9 
Low 1.0 ± 0.0 1.1 ± 0.8 
Medium 1.5 ± 0.8 0.8 ± 0.7 
High 1.4 ± 0.5 0.9 ± 0.9 
Sham 0.7 ± 0.5 0.1 ± 0.3 
Figure 11. This figure shows representative fluorescence images of all groups at the three 
different time points, as well as one image merged, respectively overlaid together. At six 
weeks, enhanced bone activity in the injected region could be detected especially for the 
treatment groups with a medium and high concentration. This localized bone activity 
decreased at 12 weeks and, with the degradation of the material, finally disappeared at  
16 weeks. In the sham group, only the area next to the needle track was enhanced. Note 
that the area of bone deposition is broader in its diameter in the treated groups compared to 
the matrix alone. 
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At six weeks, all treatment groups showed enhanced bone activity in the injected area, as indicated 
by calcein green precipitation. Overall differences between groups in bone activity were significant at  
p = 0.003. Especially in the groups with medium and high TGplPTH1-34 concentrations, the bone 
activity was enhanced with significantly higher values in comparison to the sham group (p = 0.029 and 
p = 0.040 for groups with medium and high concentration, respectively). This localized bone activity 
decreased at 12 weeks (xylenol orange) and finally disappeared at 16 weeks (tetracycline) proportional 
to the degradation of the material. For the treatment group with matrix only and for the group with a 
low concentration of TGplPTH1-34, higher scores were given at 12 weeks versus six weeks, with other 
treatment groups maintaining stable values during that period. In the sham group, only the area next to 
the needle track was enhanced for bone activity, which was attributed to the remodeling process of 
bone debris created by the needle.  
3.2.4. Histologic and Cellular Evaluation  
Means and SD of the semi-quantitative histology scoring are summarized in Table 6.
Table 6. Means and SD of the semi-quantitative histology scoring are given using the 
average of the three scoring areas for each augmentation site.  
Group 
Mononuclea
r cells 
Macro-
phages 
Multinucleate
d foreign body
cells
Fibro-
blasts 
Osteo-
clasts 
Amount of 
osteoid 
seam 
Thickness
of osteoid 
Residual 
material 
Matrix 
alone 
1.2 ± 0.4 1.1 ± 0.6 0.0 ± 0.0 0.2 ± 0.3 0.3 ± 0.4 0.7 ± 0.5 0.7 ± 0.5 0.3 ± 0.5 
Low 1.3 ± 0.3 1.2 ± 0.5 0.2 ± 0.2 0.0 ± 0.0 0.5 ±0.3 1.2 ± 0.6 1.3 ± 0.6 0.1 ± 0.1 
Medium 1.2 ± 0.4 1.0 ± 0.2 0.1 ± 0.2 0.0 ± 0.0 0.5 ± 0.4 1.1± 0.7 1.2 ± 0.7 0.0 ± 0.0 
High 1.0 ± 0.2 0.6 ± 0.3 0.0 ± 0.0 0.0 ± 0.0 0.5 ± 0.4 1.2 ± 0.4 1.3 ± 0.3 0.0 ± 0.0 
Sham 0.9 ± 0.8 0.2 ± 0.4 0.0 ± 0.0 0.0 ± 0.0 0.5 ± 0.4 0.4 ± 0.3 0.5 ± 0.3 0.0 ± 0.0 
 
The semi-quantitative histology scoring revealed similar values for all groups. Overall differences 
between groups were only found for scores of macrophages (p = 0.000). Due to the degradation 
process of the biomaterial, the number of macrophages was significantly higher in 3/4 treatment 
groups compared to the sham group (the p-value was 0.003, 0.001 and 0.009 for groups with matrix 
only, low and medium concentrations, respectively). However, the low scores of all treatment groups 
in comparison to the sham group for mononuclear cells and multinucleated foreign body cells 
indicated an excellent biocompatibility for all formulations. Thick osteoid seams and activated  
round-shaped osteoblasts evidenced an improved bone activity with higher scores found for all 
material groups containing TGplPTH1-34 (Figure 12). Residual biomaterial was found only for the 
matrix only and low concentration groups. 
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Figure 12. This figure shows a thin section with many macrophages (!) and a thick 
osteoid seam with activated round-shaped osteoblasts (!).  
 
4. Discussion  
In this study, a novel animal model in sheep was successfully established by using the cervical 
vertebrae of 17 sheep for the augmentation of cancellous bone with a biomimetic agent. The surgical 
and evaluation methods proved to be well standardized and highly reproducible. In addition, the 
efficacy of locally-delivered TGplPTH1-34 incorporated in a fibrin matrix containing strontium 
carbonate was demonstrated to be a potentially suitable augmentation material for the cervical vertebra. 
The surgical method was straightforward and easy to apply, with the aid of the specially developed 
aiming device. Using fluoroscopic imaging during the surgical procedure, combined with the various 
analyses, such as µCT, histomorphometry and sequential fluorescence dye staining, we were able to 
demonstrate that drilling and subsequent needle placement was accurate and reproducible. Consequently, 
we were able to inject test materials in 43/45 augmentation sites into the intertrabecular spacing of 
cervical vertebral bodies again with accuracy and reproducibility. However, as already discussed in a 
previous study concerning the tibia and femur augmentation in sheep [20], the trabecular bone density, 
as well as the trabecular thickness is much higher in sheep than in humans, such that the needle 
placement and material injection is more difficult to achieve in comparison to humans. In osteoporotic, 
brittle human bone, the injection needle can be placed in position using manual pressure only, whereas 
in sheep, a hole had to be drilled with a burr first in order to be able to push the needle forward into the 
healthy and dense trabecular bone. However, in contrast to the tibia and femur augmentation study, 
where a mallet had to be used after drilling to push the needle forward into the bone, this was not 
required for cervical bone augmentation. Therefore, the frequently observed surgical complications in 
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the previous study, where the rather frail needle broke during the extraction procedure, were 
significantly less frequent in the current study (1/45). The harvesting method of the treated vertebrae 
was easy, fast and highly reproducible, with no need for an additional aiming device to define the 
region of interest as needed in the previous study [20].  
Cardiovascular emboli are noticed in human patients after vertebral augmentation, even with a 
reported mortality rate of 2%. Emboli were also reported in our previously established femoral and 
tibia augmentation model [20]. Nevertheless, this cervical vertebral model presented more challenges 
regarding cardiovascular complications in comparison. Although the same material was used in both 
studies, the cervical augmentation model revealed a relatively high rate of pulmonary emboli, with two 
animals (11.76%) dying immediately on the table with severe signs of PE and five animals (29.4%) 
still showing mild signs of PE. In the femoral and tibia augmentation model, a higher leakage of 
material into the vessels was observed. This may be attributed to the different anatomical location, but 
probably also to the higher volume of material injected in the femoral and tibia augmentation model 
(3.5 mL per augmentation site). In human patients, reported emboli are less, but then, they are not 
routinely followed by lung CT after augmentation and, therefore, may often go unnoticed as long as no 
life threatening complication jeopardizes the patient’s life. The higher mortality rate in sheep 
compared to humans may be related to the fact that injection of a relatively high material volume was 
performed in healthy cancellous bone of the vertebral body and that the sheep have denser bone 
compared to humans. Nevertheless, the cervical augmentation model presented the valuable 
opportunity to study the development of PE and its consequences, as they also occur in humans during 
vertebroplasty [32].  
Mechanical testing of the vertebral bodies was not performed. Apart from technical problems to 
develop an adequate testing system with highly standardized cubes, it also was not of high priority in 
this study. One of the main reasons was that we did not treat osteoporotic sheep, since there is no 
adequate large animal model for this disease. Although we assumed that new bone formation with 
highly active osteoblast activity on new osteoid seams would be visible, it was not expected to 
significantly change trabecular thickness in healthy animals, since the mechanical load on the 
vertebrae had not changed. Trabecular thickness was only measured in µCT, where only calcified 
tissue is measured. However, in the histology sections, the increased trabecular thickness due to 
osteoid deposition is clearly visible in the ground and thin sections. 
The three different concentrations (low, medium, high) of TGplPTH1-34 proved to be suitable for 
cervical augmentation in sheep and showed indications of enhanced localized bone activity in all 
groups, especially during the first six weeks after surgery. Micro CT analysis, histomorphometry, as 
well as the evaluation of fluorescent incorporation indicated an increased bone formation and 
remodeling activity spatially limited to the injected area. As in the previous study [20], sequential 
fluorescent dye images indicated a radial propensity for new bone forming gradually over time from 
the periphery towards the middle of the injected regions. These findings support the hypothesis of 
Arrighi et al. that cell migration and infiltration into the fibrin matrix activate and release TGplPTH1-34 
into the surrounding tissue [19]. Our results further confirm those of Yang et al. showing that locally 
applied strontium has inherent osteoinductive properties itself [25]. However, combining strontium 
with high and probably even better medium concentrations of TGplPTH1-34 enhanced the overall 
proliferative effect that was already previously demonstrated by our group in the femoral and tibia 
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augmentation model [20]. The exact mechanism by which this co-effect is exerted is not fully known. 
However, we hypothesize that the accumulation of extracellular matrix induced by strontium increases 
the migration and infiltration of cells into the fibrin matrix and may also reduce osteoclast activity via 
apoptosis, again enhancing bone formation [25]. PTH, on the other hand, has anabolic activities on 
osteoblasts, increasing remodeling activity, as clearly shown in our previous study [20]. Taken 
together, bone forming properties are therefore enhanced by both ways: the increased osteoblastic 
activity through PTH and the increased population of living cells throughout the extracellular matrix 
population via strontium. Our evaluation methods did not allow distinguishing between increased 
remodeling activity and true new bone formation, as would be found in true osteoinduction. However, 
if in our current study, the different groups are compared to each other, it is obvious that the groups 
treated with TGplPTH1-34 showed considerable increased bone formation compared to the matrix alone 
group. If the material alone in combination with trabecular microdamage would be the reason for the 
new bone formation, the matrix alone and with TGplPTH1-34-treated groups would be equal in their 
response. However, the differences in new bone deposition are clearly visible in the fluorescent 
sections. Therefore, it is safe to assume that the new bone formation is in response to both remodeling 
activity after material injection and new bone formation after local application of TGplPTH1-34. 
The broad precipitation of fluorescence markers at six weeks post-surgery for the groups with 
medium and high concentrations of TGplPTH1-34 indicate an enhanced, early and fast bone formation, 
which could be confirmed by histomorphometry with the highest percentage of new bone formation 
(32.0%) found for the medium concentration of TGplPTH1-34, followed by 27.5% new bone formation 
found for the high concentration of TGplPTH1-34. In comparison, groups with fibrin matrix only or 
with low concentration of TGplPTH1-34 revealed less overall bone activity and at a later time point  
(12 weeks). This seems connected to the findings in the µCT analysis, where low quantities of residual 
material for the groups without or with a low dose of TGplPTH1-34 could be related to higher amounts 
of remaining material. We assume that the degradation of these formulations is decelerated and 
therefore reduces the bone enhancing activity due to the delayed release of activated TGplPTH1-34. To 
prove this theory in a future study, an earlier time point for the first fluorescence injection could be 
taken into consideration in order to confirm that the enhanced bone activity of medium and high 
concentrations of TGplPTH1-34 shows a faster degradation of material, in correlation with a stronger 
enhanced bone activity.  
In systemic applications of TGplPTH1-34, a great concern is that high PTH concentrations may 
increase osteoclast activity [33]. This may be reflected by a lower percentage of newly formed bone, in 
addition to increased bone resorption zones and higher numbers of osteoclasts. Due to the mechanism 
of PTH, the influence on osteoclasts must be evaluated, when PTH is applied as a local peptide. In this 
study, no increase of osteoclasts and no resorption zones were found for any of the PTH 
concentrations. These findings were attributed to the use of the peptide covalently bound to the fibrin 
matrix that is only released and activated via local cell invasion and enzymatic cleavage. We therefore 
suggest that the osteoclast-enhancing effect of PTH shown by others depends not only on the higher 
dose, but mainly on the route of administration, which could be avoided by delivering the peptide 
locally and covalently bound to the fibrin matrix.  
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5. Conclusion 
The cervical augmentation model in sheep described in this study proved to be a suitable animal 
model to evaluate the biocompatibility and new bone formation properties of new biomaterials, 
intended for vertebral bone augmentation. Although the model revealed to be more challenging, due to 
cardiovascular complications compared to the femoral and tibia augmentation model, this reflected 
well the human situation. Nevertheless, the results demonstrated that the TGplPTH1-34 was safe to use 
in sheep, since no signs of inflammation were detected and fast biomaterial degradation took place. All 
treatment groups were more effective than the sham control. Among these, the medium concentration 
of TGplPTH1-34 induced the best bone enhancing effect. Whether this effect would also be elicited in 
osteoporotic bone in humans is speculative at this point. Due to the absence of a true osteoporotic large 
animal model, this could only be verified in a clinical trial study in humans. 
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4 General Discussion and Outlook  
This   thesis  presents   two  novel   in   vivo   animal  models   for   augmentation  of   cancellous  
bone  in  sheep  while  also  investigating  new  bioactive  and  biodegradable  materials  for  
prophylactic   augmentation   of   bones   at   risk   for   osteoporotic   fractures.   Metaphyseal  
regions   like   the   proximal   femur,   proximal   humerus,   distal   radius,   and   the   vertebrae  
have   the   highest   risk   for   fragility   fractures   in   humans   [9].   In   our   animal   models  
presented,  the  proximal  tibia  and  distal  femur  of  both  hind  limbs  (first  animal  model)  
and  three  cervical  vertebrae  (second  animal  model)  were  chosen  as  augmentation  sites.  
Similarly  to  common  fragility  fracture  regions  in  humans,  the  selected  anatomical  sites  
in  our  animal  models  consist  of  high  proportions  of  cancellous  bone.  The  lower  muscle  
mass   present   at   the   injection   sites,   however,   constitute   a   marked   advantage   in   our  
models,  when  compared  to  the  human  clinical  situation.  Indeed,  our  model  favors  an  
easier  and  safer  access  to  the  bone.  With  a  total  of  four  augmentation  sites  for  the  tibia  
and   the   femur  model   and   three   for   the   cervical  model,   the   total   number   of   animals  
could   be   reduced.   For   each   model,   a   customized   aiming   device   was   developed   to  
ensure  high  reproducibility  and  accuracy  of  biomaterial  distribution  within   the   inter-­‐‑
trabecular   spacing   of   the   intact   bones.  Minimal   invasive   surgical   techniques   further  
reduce   pain   and   suffering   of   study   animals   recruited.   The   standardized   harvesting  
methods   produced   comparable   bone   samples   of   cement   loaded   bone   regions   and  
therefore,  assured  a  highly  standardized  evaluation.    
Both   animal   models   have   proven   to   be   suitable   to   evaluate   biocompatibility,  
biodegradability,   and   osteoconductive   properties   of   new   biomaterials   intended   for  
prophylactic  augmentation  of  cancellous  bone.  In  addition,  these  models  have  proven  
to  be  adequate  for  studying  the  consequences  of  extravasation  of  bone  marrow  and  fat  
cells   as   well   as   augmentation   material   into   surrounding   tissue   and   the   circulation.  
Extravasation  may   cause   serious   complications   in   both,   humans   and   study   animals,  
such   as   severe   neurological   deficits   with   paraplegia   or   pulmonary   embolism   with  
subsequent  cardiovascular  complications.  Asymptomatic  material  extravasation  in  the  
studies  presented  here  seemed  more  frequent  than  in  human  clinical  cases.    
Reasons   for   this   higher   frequency   may   be,   firstly,   the   presence   of   normal   dense  
trabecular   bone   in   the   non-­‐‑osteoporotic   sheep   model   as   opposed   to   the   diminished  
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structural   properties   of   osteoporotic   trabecular   bone   and  massive   bone   loss   typically  
found   in  menopausal  women.  Due   to   the  dense   trabecular   structure   in   sheep,  higher  
injection   pressures   are   required   for   interosseus   deposit   and   may   lead   to   increased  
extravasation   of   bone   marrow   fat   and/or   material.   Secondly,   it   is   possible   that   the  
material   itself,  under  the  given  circumstances,  favors  extravasation.  Indeed,  Bohner  et  
al.   considered   the   frequency  of   extravasation   to  be   influenced  by   several  parameters:  
Bone   permeability,   bone  marrow   and   cement   viscosity,   bone   porosity   and  pore   size,  
size   of   injection   cavity,   diameter   of   extravasation   path,   and   injected   cement   volume  
[61].  Material  xtravasation  has  been  associated  mostly  with  low  viscosity  materials  and  
is   therefore   not   considered   a   primary   factor   in   our   model   where   a   high   viscosity  
material   was   used.   Thirdly,   in   most   asymptomatic   clinical   patients   following  
vertebroplasties,   no   routine   chest   radiographs   or   CTs   are   performed   and   therefore  
regional  or  systemic  cement   leakage  and  pulmonary  cement  emboli  may  often  not  be  
detected  [101,106,174].    
Although   the   tested   biomaterials   are   intended   for   prophylactic   augmentation   of  
osteoporotic  bone  with   low  BMD  and  change   in   trabecular  bone  architecture,  we  did  
not   use   osteopenic   or   osteoporotic   animals.   In   our   opinion,   to   date   there   is   no   true  
osteoporotic   large   animal   model   available.   Some   research   groups   have   used  
ovariectomized   sheep,   but   even   in   those   animals   a   marked   bone   loss   could   not   be  
detected  [154,160].  A  combination  of  ovariectomy,  glucocorticoid  treatment  and  highly  
anionic   diet   has   shown   to   induce   a   more   prominent   loss   of   BMD   and   trabecular  
thickness   in   sheep   [156-­‐‑159].   However,   such   a   combined   bone   loss   induction  model  
does  present  with  rather  significant  difficulties:  
1)   Pathogenesis   of   osteoporosis   in   postmenopausal   women   has   a   different  
underlying   cellular   mechanism.   However,   postmenopausal   women   represent   the  
largest  patient  group  in  humans  [175].  
2)  Glucocorticoid  administration  may  lead  to  infections  due  to  immunosuppression,  
as  well  as  joint  pain  with  lameness,  and  therefore  ethical  considerations  compromise  
acceptance  of  the  model.    
3)  The  glucocorticoids  may  influence  the  bioactivity  of   test  materials  and  therefore  
bias  the  study  outcome.    
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The   tibia   and   femur   augmentation   model   proved   suitable   for   testing   different  
biomaterials   with   the   advantage   to   reduce   the   total   number   of   animals   und   the  
suffering  of  each  individual  animal.  Whereas  the  tibia  and  femur  augmentation  model  
with   four   easily   accessible   augmentation   sites   per   animal,   is   a   suitable   model   for  
preliminary   screening   studies   of   different   material   formulations,   the   cervical  
augmentation  model  reveals  to  be  technically  more  challenging,  but  is  topographically  
closer   to   the   human   situation.   The   cervical   augmentation   model   was   also   closer   to  
clinical   reality   with   a   more   severe   and   a   higher   number   of   cardiovascular  
complications.  Although  for  both  animal  models  material  as  well  as   fat  extravasation  
were   detected   (using   fluoroscopy   during   augmentation   and   a   postoperative   thorax  
CT),   the  clinical  complications  of   the  cervical  augmentation  model  were  more  severe.  
Two   of   seventeen   animals   in   the   cervical   augmentation   study   died   intraoperatively  
(11.76%)  with  29.4%  of  the  animals  showing  mild  symptoms  of  pulmonary  embolism.  
The  exact  reasons  for  these  higher  complication  rates  is  unknown,  it  might  be  though  
due  to  the  high  vascularization  of  the  vertebral  body  in  the  relatively  high  volume  of  
injected   material   into   healthy,   physiologically   dense   bone.   In   humans   the   detected  
complications   are   fewer,   but   similar   in   nature   and   thus,   the   cervical   augmentation  
model  may  in  the  future  well  serve  to  study  and  possibly  reduce  severe  cardiovascular  
complications.  
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